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Abstract 
We designed a population-based cohort study to describe the characteristics and 
outcomes of 6346 adults discharged home from an emergency department (ED) with 
acute kidney injury (AKI). Within 30 days of discharge, 149 (2.3%) patients died (stage 
1: 2.1%, stage 2: 5.2%, and stage 3 AKI: 15.9%). We also compared 30-day mortality to 
patients hospitalized with AKI and patients discharged home with no AKI in two separate 
propensity score-matched analyses. An ED discharge versus hospitalization was 
associated with lower 30-day mortality (3.0% vs. 11.9%, relative risk (RR): 0.25, 95% 
confidence interval (CI): 0.21-0.30). An ED discharge home with AKI versus no AKI 
was associated with higher 30-day mortality (2.2% vs. 1.4%, RR: 1.56, 95% CI: 1.20-
2.04). Although sicker patients are appropriately hospitalized, patients discharged home 
from the ED with AKI remain at risk of adverse outcomes. A better understanding of care 
appears warranted, as is testing strategies to improve care. 
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Glossary of Terms 
Acute kidney injury a sudden deterioration in kidney function over a period of 
hours to days, defined by relative changes in serum 
creatinine concentration from baseline. 
Admission the need for patient care under a medical service in the 
hospital setting. 
Aggregated Diagnosis 
Group 
a point score derived from the John Hopkins Adjusted 
Clinical Groups® system. It is a weighted measure of health 
care utilization as a proxy measure for co-morbidity and 
accounts for the duration of condition, severity of condition, 
diagnostic certainty, etiology of the condition, and specialty 
care involvement. 
Albumin-to-creatinine 
ratio 
a ratio between urine albumin and urine creatinine. It is used 
to diagnose and monitor kidney disease. 
Angiotensin II receptor 
blocker 
a class of medication that blocks (inhibits) the binding of 
angiotensin II to its receptor on smooth muscles surrounding 
blood vessels. As a result, blood vessels enlarge or dilate, 
and blood pressure is reduced. This medication also benefits 
patients with heart and chronic kidney disease. 
Angiotensin-converting 
enzyme inhibitor 
a class of medication that slows (inhibits) the activity of the 
enzyme angiotensin-converting enzyme, which decreases 
the production of angiotensin II. As a result, blood vessels 
enlarge or dilate, and blood pressure is reduced. This 
medication also benefits patients with heart and chronic 
kidney disease. 
Anti-retroviral one of several classes of medications used to control an HIV 
(a retrovirus) infection. 
Anticoagulant commonly referred to as blood thinners, a class of 
medication that prevents or reduces the coagulation of 
blood, prolonging the clotting time. 
 xv 
 
Antiplatelet a class of medication that decreases the ability of a blood 
clot to form by interfering with platelet activation (clumping 
or aggregation). 
Antipsychotic also known as neuroleptics or major tranquilizers, a class of 
medication used to manage psychosis (delusions, 
hallucinations, paranoia or disordered thought), principally 
in schizophrenia and bipolar disorder. 
Abdominal aortic 
aneurysm 
an enlargement of the abdominal aorta (main artery of the 
human body). 
Atrial fibrillation or 
flutter 
atrial fibrillation is an abnormal heart rhythm characterized 
by rapid and irregular beating by the top chambers (atria) of 
the heart. Atrial flutter is characterized by a rapid, regular 
beating by the atria. 
Beta-adrenergic 
antagonist 
commonly referred to as a beta-blocker, a class of 
medication that blocks the beta receptors of the adrenergic 
sympathetic nervous system (flight or fight response), which 
are located on a number of organs (e.g. kidneys, heart, 
arteries). The net effect depends on the organ and type of 
beta receptor. Effects include (but not limited to) the 
reduction of heart rate and/or blood pressure. 
Calcium channel 
blocker 
also known as calcium channel antagonist, a class of 
medication that disrupts the movement of calcium. 
Depending on the type of calcium channel blocker, the net 
effect is a reduction of blood pressure by relaxing smooth 
muscle in blood vessels or the slowing of the heart rate by 
depressing the atrioventricular node in the heart. 
Canadian Triage Acuity 
Scale 
a system that categorizes patients by both injury and 
physiological findings, and ranks them by severity from 1–5 
(1 being highest). The model is used by both paramedics 
and Emergency Department nurses, and also for pre-arrival 
notifications. 
 xvi 
 
Cerebrovascular disease Vascular disease of the cerebral circulation involving 
arteries supplying oxygen to the brain. A stroke is a 
manifestation of cerebrovascular disease. 
Charlson co-morbidity 
index 
also known as the Charlson score, an index that predicts the 
one-year mortality for a patient who may have a range of 
co-morbid conditions. The Charlson co-morbidity index is 
based on the International Classification of Diseases 
diagnosis codes found in administrative data. 
Chronic kidney disease the progressive loss in kidney function over a period of 
months or years. 
Chronic liver disease progressive disease of the liver over a period of at least six 
months. 
Chronic obstructive 
pulmonary disease 
a progressive obstructive lung disease characterized by 
long-term breathing problems and poor airflow. Symptoms 
include shortness of breath, cough, and sputum production. 
Coronary angiogram a minimally invasive procedure to access the coronary 
circulation and blood-filled chambers of the heart using a 
catheter.  
Coronary artery disease disease in which a blockage (such as a waxy substance 
called a plaque) develops inside the coronary arteries. 
Coronary arteries supply oxygen-rich blood to the heart 
muscle. An acute myocardial infarction (heart attack) is a 
manifestation of coronary artery disease. 
Coronary events a term researchers and clinicians use to encompass a number 
of important outcomes for patients with heart disease. These 
outcomes may include myocardial infarction, ischemic heart 
failure, unstable angina, sudden death, and procedures such 
as a coronary angiogram or coronary artery bypass surgery. 
Corticosteroid a class of synthetic steroid hormone medication that reduces 
inflammation and suppresses the immune system through a 
variety of mechanisms. 
 xvii 
 
Creatinine a byproduct of muscle breakdown that appears in the blood, 
is filtered by the kidneys, and excreted in the urine. 
Dementia a set of symptoms that are caused by disorders affecting the 
brain. Symptoms include memory loss, difficulties with 
thinking, problem-solving or language, which may be severe 
enough to reduce a person's ability to perform everyday 
activities. 
Dialysis the process of removing waste products and excess fluid 
from the body through a machine. Dialysis is necessary 
when the kidneys are not able to adequately filter toxins and 
waste products from the blood. 
Discharge the release of a patient from a course of care, typically 
referring to a patient who leaves hospital and goes home. 
Disposition the plan for continuing health care of a patient following 
discharge or transfer from a given health care facility. 
Diuretic a class of medication that increases production of urine 
(diuresis). Fluid (water and electrolytes) is excreted from the 
body by the kidney, which may result in blood pressure 
reduction. Certain diuretics promote the excretion of 
potassium (non-potassium sparing) while others do not 
(potassium-sparing). 
Echocardiogram an ultrasound of the heart. 
Electronic health record also known as an electronic medical record, a collection of 
patient electronically-stored health information in a digital 
format, which may supplement or replace a physical (paper) 
form of the medical chart. 
End-stage kidney 
disease 
the final stage of chronic kidney disease in which the 
kidneys do not function well enough to meet the needs of 
daily life. At this stage, renal replacement therapy is 
required to sustain life. 
 xviii 
 
Glomerular filtration 
rate 
the sum of all filtration rates of all functioning nephrons in 
the kidney. This metric is used to assess kidney function in 
routine care. 
Heart failure also known as congestive heart failure, heart failure occurs 
when the heart is unable to pump sufficiently to maintain 
blood flow to meet the body's needs. 
Hypertension elevated blood pressure. 
Immunosuppressive 
medication 
a class of medication that suppresses or reduces the strength 
of the body's immune system. Corticosteroids are also 
considered immunosuppressive medications. However, they 
have been separated into a class of their own in this study. 
Kidney transplant 
rejection 
the process of when a transplanted kidney is rejected by the 
person’s (recipient’s) immune system, destroying the 
transplanted tissue. 
Lower urinary tract 
symptoms 
a group of clinical symptoms involving the bladder, urinary 
sphincter, urethra, and, in men, the prostate. 
Myocardial infarction also known as a heart attack, the blockage of blood flow to a 
section of the heart. If blood flow is not restored quickly, 
that section of the heart begins to die and the level of 
damage depends on how long blood supply is cut off. 
Nephrolithiasis kidney stones. 
Nephron the basic structural and functional unit of the kidney. The 
chief function of the nephron is to regulate the concentration 
of water, soluble substances, and metabolic waste products 
substances by filtering the blood, reabsorbing what is 
needed, and excreting the rest as urine. 
Non-steroidal anti-
inflammatory drug 
a class of medication used to reduce pain, decrease fever, 
and decrease inflammation. Non-steroidal anti-inflammatory 
drugs work by inhibiting the activity of cyclooxygenase-1 
and cyclooxygenase-2 (COX-2) enzymes, thereby inhibiting 
the synthesis of prostaglandins and thromboxanes. 
 xix 
 
Oral hypoglycemic 
agents 
also known as anti-hyperglycemic agents, a broad class of 
medications aimed to lower blood glucose levels. 
Mechanism of action depends on the type of oral 
hypoglycemic agent. 
Osteoarthritis a degenerative joint disease also known as “wear and tear” 
arthritis. The cartilage or cushion between joints breaks 
down leading to pain, stiffness and swelling. 
Outpatient a patient who receives medical treatment without being 
admitted to a hospital. 
Palliative care a multidisciplinary approach to specialized medical and 
nursing care for people with life-limiting illnesses, focusing 
on providing people with relief from the symptoms, pain, 
physical stress, and mental stress of the terminal diagnosis. 
Parkinson’s disease a progressive disorder of the nervous system that affects 
movement. 
Peripheral vascular 
disease 
also known as peripheral arterial disease, the narrowing of 
the blood vessels other than those that supply the heart or 
the brain. 
Proton pump inhibitor a class of medication that reduces gastric (stomach) acid 
production. Proton pump inhibitors block the 
hydrogen/potassium adenosine triphosphatase (ATP) pump 
found in gastric cells. 
Renal replacement 
therapy 
a therapy that replaces the normal blood-filtering function of 
the kidneys. Renal replacement therapy is a broad term that 
refers to all types of dialysis modalities as well as kidney 
transplantation. 
Revascularization the restoration of perfusion to a body part or organ that has 
suffered ischemia (reduction of blood supply resulting in the 
shortage of oxygen in tissues). It is typically accomplished 
by surgery. Vascular bypass and angioplasty are two 
primary methods of revascularization. 
 xx 
 
Rheumatoid arthritis a long-term autoimmune disorder that primarily affects 
joints. It typically results in warm, swollen, and painful 
joints. In a person with an autoimmune disorder, their 
immune system attacks their own body’s tissues. 
Statin a class of lipid-lowering (cholesterol) medications that 
inhibit the HMG-CoA (3-hydroxy-3-methyl-glutaryl-
coenzyme A) reductase enzyme, which plays a central role 
in the production of cholesterol. 
Ultrasound an imaging method that uses high-frequency sound waves to 
produce images of structures within the body. 
Uricosuric agents a class of medication used to treat or prevent gout. 
Uricosuric medications promote excretion of uric acid in the 
urine. 
Urine albumin  also known as albuminuria, the presence of albumin in the 
urine. The amount of urine albumin is not expected to 
exceed a threshold of 150 mg per day in patients with 
normal kidney function. Albumin is a protein made by the 
liver. 
Urine dipstick also known as a urine test strip, a basic diagnostic tool used 
to determine if there are abnormal changes in a patient’s 
urine. A standard urine dipstick may comprise of several 
tests. Common tests include protein (albumin), glucose, 
white blood cells, and hemoglobin (a component of red 
blood cells). 
Xanthine oxidase 
inhibitors 
a class of medication used to treat or prevent gout. Xanthine 
oxidase inhibitors slow the enzyme xanthine oxidase, which 
is involved in the production of uric acid. 
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Chapter 1  
1 Introduction 
Acute kidney injury (AKI) is the sudden deterioration of kidney function which affects at 
least 10% of hospitalized patients.1–3 AKI associates with increased morbidity, mortality, 
and health care costs exceeding $10 billion annually in the United States.4–7 
Our understanding of AKI epidemiology is largely informed by studies conducted in 
hospitalized and critically ill patients.1,3,4,8 Less is known about patients who present to 
the emergency department (ED), have evidence of AKI, and are discharged home. A 
discharge home may mean the ED health care staff felt the AKI was reversible and could 
be managed as an outpatient in the community or it may represent an unrecognized 
population at risk of adverse outcomes. 
 
As of August 10, 2017, no study has described the characteristics and adverse outcomes 
of patients discharged home from the ED with AKI in comprehensive detail, nor has any 
study compared these outcomes to other relevant ED patient groups. To address this 
knowledge gap, we conducted a population-based cohort study to describe the 
characteristics and outcomes of this AKI subpopulation. To provide context to our 
results, we used propensity score methods to investigate whether an ED discharge home 
with AKI compared to an admission to hospital, or ED discharge home with no AKI, is 
associated with an altered risk of 30-day all-cause mortality. 
 
This thesis is structured into the following chapters: 2 Literature Review, 3 Rationale and 
Research Questions, 4 Methods, 5 Results, and 6 Discussion. In Chapter 2, we provide an 
explanation of normal kidney function and define AKI. We then describe our current 
understanding of AKI epidemiology. Finally, we highlight a knowledge gap regarding 
patients discharged home from the ED with AKI. In Chapter 3, we state our research 
questions and rationale for each question. In Chapter 4, we provide a detailed summary of 
our methods. In Chapter 5, we present our results with accompanying figures and tables. 
In Chapter 6, we discuss our findings and their implications relative to our current 
2 
 
understanding of AKI in the community and in hospital. Finally, we discuss the strengths 
and weaknesses of this work and conclude with recommendations for future research. 
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Chapter 2  
2 Literature Review 
 
2.1 The Normal Kidney 
2.1.1 Overview of Kidney Function 
The kidney is a vital organ with several key functions. These functions include the 
excretion of metabolic waste products such as urea and creatinine, regulation of fluid and 
electrolytes such as sodium and potassium, and the production of hormones that regulate 
local and systemic processes involved in hemodynamics, bone mineral metabolism, and 
the production of red blood cells.9 
 
2.1.2 Measurement of Kidney Function 
The kidney is comprised of millions of nephrons, which are the main filtration units of 
the kidney.9 The sum of all functioning nephron filtration rates is called the glomerular 
filtration rate (GFR).10 Certain waste products of metabolism have specific properties that 
make them suitable candidates as biomarkers to estimate the GFR.10  The most common 
biomarker used by clinicians is serum creatinine (SCr). SCr is a byproduct of muscle 
metabolism that is filtered and excreted unchanged by the kidneys.10 Despite the 
availability of other biomarkers such as cystatin C, SCr remains the most convenient and 
cost-effective test for measuring kidney function in routine care.11 SCr concentrations are 
incorporated into an equation to calculate the estimated GFR (eGFR).10 The Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is a recent and 
accepted method of calculating the eGFR. Developed in 2009, the CKD-EPI equation has 
replaced the Modification of Diet in Renal Disease (MDRD) equation because of greater 
precision and accuracy.12 All GFR-estimating equations assume relative stability in SCr 
concentrations over time and cannot be used to assess abrupt changes in kidney 
function.10,13 Because of this major limitation, clinicians continue to rely on relative 
changes in SCr concentrations to assess AKI.14 
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2.2 Acute Kidney Injury 
AKI is serious clinical condition defined by a sudden loss of kidney function, which 
results in the rapid accumulation of waste products, fluids, and electrolytes.10 Acute 
kidney injury replaces the term acute renal failure following the recognition that smaller 
decrements in kidney function are clinically relevant.14 The term AKI will be used 
throughout the entire thesis. 
 
2.2.1 Definition of Acute Kidney Injury 
The use of relative changes in SCr concentration is considered the standard of care for the 
detection of AKI. Standardized, consensus definitions for AKI have been developed for 
use in the general population (Table 2-1). The most recent consensus definition for AKI 
was developed by the Kidney Diseases: Improving Global Outcomes (KDIGO) AKI 
working group in 2012,14 adapted from two criteria: RIFLE (Risk, Injury, Failure, Loss, 
End-stage renal disease) in 2004,15 and AKIN (Acute Kidney Injury Network) in 2007.16 
 
Table 2-1: Diagnostic Criteria for Acute Kidney Injury 
Criteria SCr criteria Urine output criteria RIFLE15 AKIN16 KDIGO14 
Definition Relative 
increase in SCr 
from baseline 
of ≥50% 
developing 
within 7 days 
Relative increase 
in SCr of ≥26.5 
µmol/L or ≥50% 
from baseline 
developing within 
48 hours 
Absolute increase 
in SCr of ≥26.5 
µmol/L developing 
within 48 hours or 
relative increase 
≥50% developing 
within 7 days 
Urine output 
of <0.5 
mL/kg/hour 
for >6 hours 
Adapted from the 2012 KDIGO clinical practice guidelines for AKI.14 
 
AKI can be diagnosed when one of the following criteria is met: (1) SCr increase of 
≥26.5 µmol/L within 48 hours; (2) a 50% increase or more from baseline (compared to a 
known or suspected baseline value) within seven days; (3) a reduction in urine output to 
<0.5 mL/kg/day for at least six hours.14 AKI can be stratified into three stages of severity. 
Stage 1 AKI is defined as a relative increase in SCr ≥50% to <100% within seven days, 
an absolute increase in SCr of ≥26.5 µmol/L within 48 hours, or a decrease in urine 
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output to <0.5 mL/kg/hour for 6 to <12 hours. Stage 2 AKI is defined as a relative 
increase in SCr value of ≥100% to <200% from baseline within seven days or a reduction 
in urine output to <0.5 mL/kg/hour for 12 to <24 hours. Stage 3 AKI is defined as a 
relative increase in SCr value of >200% from baseline or an increase in SCr value to 
≥354 µmol/L within seven days, or the initiation of dialysis (renal replacement therapy). 
 
2.3 Acute Kidney Injury Epidemiology 
AKI is a serious clinical condition that affects at least 10% of all patients in hospital.1–3,17 
In the United States, the incremental health care costs attributed to AKI in hospitalized 
patients are in excess of $10 billion per year.4 Morbidity and mortality associated with 
AKI escalates with severity.4,8,18–20 Among patients who receive dialysis for the 
management of their AKI, short-term mortality exceeds 50%.8,21 Large cohort studies 
have also shown that AKI as defined by modest increments in SCr concentration (e.g. 
increase by 50% or more) independently associates with a 3.5 day increase in hospital 
length of stay and a 4.4-fold increase in mortality.4 
 
Individuals who survive an episode of AKI during hospitalization remain at risk of short 
and long-term adverse outcomes.7,18,22 Within the first 3 to 6 months, survivors of AKI 
are at 10-fold greater risk of developing de novo chronic kidney disease (CKD), at 3-fold 
greater risk of progression to end-stage kidney disease, and have double the risk of 
death.20,23,24 In the long-term AKI is associated with an increased risk of coronary events 
(non-fatal myocardial infarction, need for coronary angiogram, or coronary artery bypass 
surgery),25,26 stroke,27 and hypertension.28 Despite accumulating evidence that AKI 
survivors are a high risk group, follow-up care remains poor and inadequate.29–31 
 
2.4 Emergency Department Setting 
The ED is a common place for patients to seek health care. From 2015 to 2016, the 
Canadian Institute for Health Information (CIHI) reported that 4,865,575 adults 20 years 
and older visited an ED in Ontario, 556,786 (11.4%) of whom required admission to 
hospital.32 The reasons for the ED visits varied widely, ranging from acute abdominal and 
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pelvic pain (3.6%) to gastroenteritis (1.6%).32 The ED was also a point of access to 
receive primary care for patients with non-urgent issues despite being registered with a 
family physician.33,34 
 
The ED is an environment where visits are brief and transient.35–37 Following their 
clinical assessment, ED physicians are challenged with the task of determining the 
disposition of the patient. The patient may be discharged home to the community with or 
without outpatient follow-up, transferred to another hospital, or referred to another 
medical service to be admitted to hospital. The final decision on disposition is influenced 
by several patient-, physician-, facility-, and regional-related factors.38,39 
 
The ED is a common clinical setting for patients to present with AKI,40,41 and studies 
have primarily focused on patients admitted to hospital from the ED.42,43 However, in 
some circumstances patients with AKI who present to the ED will be discharged home 
rather than be admitted to hospital. 
 
2.5 Patients Discharged from the Emergency Department 
with Acute Kidney Injury 
2.5.1 Search Strategy and Quality Assessment of Prior Studies 
A single reviewer conducted a literature search to identify prior studies that described 
patients discharged home from the ED with AKI. MEDLINE Ovid and Pubmed were 
searched for relevant articles in March 2016. The search was updated on August 10, 
2017. The final search strategy combined two previously published search strategies for 
AKI- and ED-related studies (Appendix A).44,45 Key words included “community-
acquired”, “outpatient”, “ambulatory care”, and “primary care” because patients 
discharged home from the ED may be described in studies investigating community-
acquired AKI. The reviewer also used the related articles option in Pubmed and searched 
relevant review articles and reference lists of included articles. 
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Our inclusion and exclusion criteria were developed a priori. Any study published in 
English was eligible for review. Studies were excluded using any one of the following 
criteria: (1) duplicate studies; (2) reviews, editorial articles, or consensus guidelines; (3) 
pediatric (age less than 18 years) or non-human studies; (3) studies that did not describe 
patients with AKI; (4) studies in which AKI did not occur in the ED setting; and (5) 
studies that did not describe patients discharged home. 
 
A single reviewer screened all citations for potentially relevant articles, reviewed full-text 
articles for eligibility, and then abstracted the data from eligible studies. The same 
reviewer evaluated the quality of individual studies using the Downs and Black quality 
assessment method, a list of 27 criteria to evaluate both randomized and non-randomized 
studies.46 This scale assesses the completeness and clarity of study reporting, external 
validity, internal validity (e.g. bias and confounding), and power. The tool was modified 
slightly for use in our review. Specifically, the scoring for question 27 dealing with 
statistical power was simplified to a choice of awarding either 1 or 0 points depending on 
whether there was sufficient power to detect a clinically important effect. On the 
modified scale, we gave all included studies a score from 0 to 28, grouped into the 
following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and 
poor (14 or less). 
 
2.5.2 Summary of Previous Literature 
A study flow diagram of the literature search is shown in Figure 2-1 and from the 
beginning excludes the citation related to this thesis.47 A single reviewer screened 11,465 
articles for potentially relevant citations and selected 514 studies for evaluation. There 
were 509 articles excluded, leaving five studies which distinctly described patients who 
visited an ED, had evidence of AKI, and were discharged home (Table 2-2).48–52 
 
Three studies were from the United Kingdom,49–51 one was from the United States,48 and 
one was from Canada.52 A total of 3031 patients visited the ED, had evidence of AKI, and 
were discharged home. In all five studies, patients discharged from the ED with AKI 
were described as a subgroup of larger patient population. The 2013 study by Roghmann 
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et al. showed 71 (0.01%) of 1,066,135 patients presenting to the ED with lower urinary 
tract symptoms were discharged home with AKI.48 In 2014, Talabani et al. identified 230 
consecutive patients in the United Kingdom with community-acquired AKI who visited 
either a primary care physician or acute care centre (i.e. emergency department).49 The 
mean age of the entire cohort was 70 years and the 90-day mortality was 17%. In a subset 
of 119 patients who visited an acute care centre, 49 (41%) were discharged home. The 
2017 study by Hazara et al. used an electronic AKI alerting system to identify 1277 AKI 
episodes in 1185 patients who visited the ED.51 The mean age was 72 years, 50% were 
male, and the 30-day mortality was 25%. The authors also found 13% (161) of all AKI 
alerts represented ED patients discharged home. However, for all three studies, baseline 
characteristics and outcomes specific to patients discharged home from the ED with AKI 
were lacking. 
 
The 2016 study by Holmes et al. examined 9375 patients with AKI assessed in accident 
and emergency or acute assessment units. The mean age ranged between 68 and 71 years 
and 40 to 49% had pre-existing CKD. In a subgroup of 2719 patients (29%) discharged 
home, the 90-day mortality was 10 to 15%.50 There was no additional information on 
baseline characteristics. In 2017, Scheuermeyer et al. studied 1651 consecutive ED 
patient visits over a one-week period, 90 (6%) of whom were diagnosed with AKI.52 
Among patients with AKI, 31 (34%) were discharged home. The age ranged between 29 
and 93 years, co-morbidities were described in select cases, and there were no deaths 
within 30 days of an ED discharge home. Only four patients (13%) had renal-specific 
follow up. 
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Figure 2-1: Literature Review Flow Diagram 
 
Abbreviations: AKI, acute kidney injury; ED, emergency department. 
a Details of the literature review search strategy is shown in Appendix A. The numbers shown in the figure exclude the 
citation related to this thesis.47 
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Table 2-2: Summary of Studies Examining Patients Discharged Home from the Emergency Department with Acute Kidney Injury 
Author Year Location Population Description Key findings Limitations Quality 
score 
(0-28)a 
Roghmann et 
al. 
2013 United 
States, 
2006-2009 
1,178,423 
patients 
presenting to 
the ED with 
LUTS 
Patients stratified 
by ED disposition 
(admitted vs. 
discharged), 
various outcomes 
defined as adverse 
events, (e.g. ICD-9 
code for AKI: 584) 
Of the 1,066,135 
patients with 
LUTS discharged 
home from the ED, 
71 (0.01%) had 
AKI. 
No baseline 
characteristics 
specific to AKI 
patients. 
18 
Talabani et 
al. 
2014 United 
Kingdom 
(Cardiff), 
Apr 2009 
230 patients 
identified with 
CA-AKI on 
health region 
Patients stratified 
by type and 
location of CA-
AKI diagnosis. 
AKI defined by 
SCr values using 
KDIGO criteria. 
Outcomes included 
mortality, CKD 
progression, and 
renal recovery. 
119 patients 
diagnosed with 
AKI in an acute 
care setting (ED), 
with 49 (41%) 
discharged home. 
Descriptive study 
only. No baseline 
characteristics or 
outcomes specific 
to this subgroup of 
patients with CA-
AKI. 
17 
Holmes et al. 2016 United 
Kingdom 
(Wales), 
Mar - Aug 
2015 
17,689 AKI 
episodes 
generated using 
e-alert system 
in the health 
region 
Patients stratified 
by either CA-AKI 
vs HA-AKI, and 
AKI severity. AKI 
defined using 
KDIGO criteria. 
Outcome was 
Of the 9375 AKI 
episodes diagnosed 
in the ED, 2719 
(29%) were 
discharged home 
(similar for all 
AKI stages), 
Descriptive study. 
Except for age and 
CKD, no other 
baseline 
characteristic for 
our patient 
population of 
16 
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location of 
diagnosis and 90-
day mortality. 
respectively. The 
90-day mortality 
was 10-15%. 
interest was 
present. 
Hazara et al. 2016 United 
Kingdom 
(Kingston-
upon-Hull), 
Nov 2013 – 
Apr 2014 
1277 AKI 
episodes 
generated in 
1185 ED 
patients using 
an e-alert 
system. 
AKI defined using 
KDIGO criteria. 
Outcome was 30-
day mortality. 
Of the 1277 AKI 
episodes identified 
in the ED, 161 
(13%) AKI 
episodes (98% 
stage 1 AKI) 
represented 
patients discharged 
home.  
Descriptive study. 
No detailed 
baseline 
characteristics. 30-
day mortality not 
described for 
subgroup. 
15 
Scheuermeyer 
et al. 
2017 Canada 
(Vancouver), 
Jan 2014 
1651 unique 
patient ED 
visits screened 
for AKI in two 
EDs over a 1-
week period 
AKI defined using 
KDIGO criteria. 
Outcomes included 
follow-up SCr 
testing, mortality, 
and need for renal 
replacement 
therapy at 30 days. 
Of the 90 patients 
who had AKI, 31 
(34%) were 
discharged home. 
Four patients 
(13%) were 
deemed to have 
appropriate follow-
up and none died. 
ED diagnosis 
provided, detailed 
chart review for 
each patient. 
Small study. 
Clinical vignette 
for each case. No 
detailed list of 
baseline 
characteristics for 
subgroup. 
14 
Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired acute kidney injury; CKD, chronic kidney disease; ED, emergency department; HA-AKI, hospital-
acquired acute kidney injury; ICD, International Classification of Diseases; KDIGO, Kidney Disease: Improving Global Outcomes; LUTS, lower urinary tract symptoms; SCr, 
serum creatinine. 
a We evaluated the quality of individual studies using the Downs and Black quality assessment method, which is a list of 27 criteria to evaluate both randomized and non-
randomized trials.46 This scale assesses the completeness and clarity of study reporting, external validity, internal validity (e.g. bias and confounding) and power. The tool was 
modified slightly for use in our review. Specifically, the scoring for question 27 dealing with statistical power was simplified to a choice of awarding either 1 or 0 points 
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depending on whether there was sufficient power to detect a clinically important effect. On the modified scale, we gave all included studies a score from 0 to 28, grouped into 
the following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and poor (14 or less).
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Chapter 3  
3 Rationale and Research Questions 
 
3.1 The Need for Research 
No study has investigated the characteristics and outcomes of patients discharged home 
from the ED with AKI in detail nor has any study provided context for these outcomes by 
comparing this group to other relevant ED subpopulations. A better understanding of this 
patient population is required. 
 
The research questions and hypotheses for this study are separated into (1) a descriptive 
analysis of the characteristics and outcomes of patients discharged home from the ED 
with AKI (Chapter 3.2.1) and (2) a propensity score matching analysis (Chapter 3.2.2). 
 
3.2 Research Questions and Hypotheses 
3.2.1 Descriptive Analysis 
3.2.1.1 Primary Questions 
1) In the ED setting, what are the characteristics of patients discharged home with AKI? 
 
Hypothesis: Co-morbid conditions, such as diabetes, hypertension, and CKD and the 
use of certain medications such as angiotensin-converting enzyme inhibitors, 
angiotensin II receptor blockers, and diuretics will be common in this patient 
population. 
 
2) In the ED setting, what is the 30-day risk of all-cause mortality in patients discharged 
home with AKI? 
 
Hypothesis: Based on our literature review,48–52 the 30-day risk of all-cause mortality 
is estimated to be between 0% and 15%. This risk will increase with AKI severity. 
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3.2.1.2 Secondary Questions 
1) In the ED setting, what is the 30-day risk of receipt of hospital-based acute dialysis in 
patients discharged home with AKI? 
 
Hypothesis: Our literature search did not inform the expected rate for the receipt of 
hospital-based acute dialysis. Given these patients are discharged home rather than 
admitted to hospital, the receipt of hospital-based acute dialysis is expected is to be 
low, and increase with AKI severity.  
 
2) In the ED setting, what is the 30-day risk of five additional outcomes: (1) need for 
subsequent hospitalization after an ED discharge home, (2) at least one outpatient 
physician visit (family physician, internist, nephrologist, or urologist), (3) at least one 
outpatient SCr test, (4) at least one outpatient urine test for protein, and (5) total 
health care costs? 
 
Hypothesis: Our literature search did not inform the expected rate for these additional 
outcomes. However, these outcomes are expected to increase with AKI severity. 
 
3.2.2 Propensity Score Matching Analysis 
3.2.2.1 Primary Questions 
1) In the ED setting, does a group of patients discharged home with AKI compared to a 
group of patients admitted to hospital with AKI with similar baseline characteristics 
have an altered 30-day risk of all-cause mortality? 
 
Hypothesis: An ED discharge home with AKI will be associated with a lower risk of 
mortality compared to a hospital admission with AKI. It is expected that critically ill 
patients will be appropriately admitted to hospital for ongoing management. It is 
unlikely that an ED discharge home with AKI would confer a higher risk of mortality 
compared to a hospital admission with AKI. 
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2) In the ED setting, does a group of patients discharged home with AKI compared to a 
group of patients discharged home with no AKI with similar baseline characteristics 
have an altered 30-day risk of all-cause mortality? 
 
Hypothesis: An ED discharge home with AKI will be associated with a higher risk of 
mortality compared to an ED discharge home with no AKI. It is expected our findings 
to be similar in studies that compared hospitalized patients with AKI versus no AKI. 
 
3.2.2.2 Secondary Questions 
1) In the ED setting, does a group of patients discharged home with AKI compared to a 
group of patients admitted to hospital with AKI with similar baseline characteristics 
have an altered 30-day risk of receipt of hospital-based acute dialysis? 
 
Hypothesis: An ED discharge home with AKI will be associated with a lower risk of 
receipt of hospital-based acute dialysis compared to a hospital admission with AKI. 
 
2) In a subgroup analysis, is the association between an ED discharge home with AKI 
(versus a hospital admission with AKI) and 30-day risk of all-cause mortality 
modified by AKI stage? 
 
Hypothesis: Compared with a hospital admission with AKI, the relative association 
between an ED discharge home with AKI and all-cause mortality may be attenuated 
with an increase in AKI stage. Based on previous literature, higher stages of AKI 
associate with increased mortality in a group patients with AKI who are managed as 
outpatients.49,53 
 
3) In the ED setting, does a group of patients discharged home with AKI compared to a 
group of patients discharged home with no AKI with similar baseline characteristics 
have an altered 30-day risk of receipt of hospital-based acute dialysis? 
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Hypothesis: An ED discharge home with AKI will be associated with a higher risk of 
receipt of hospital-based acute dialysis compared to an ED discharge home with no 
AKI. 
 
4) In a subgroup analysis, is the association between an ED discharge home with AKI 
(versus an ED discharge home with no AKI) and the risk of 30-day all-cause 
mortality modified by the presence of pre-ED visit CKD? 
 
Hypothesis: Compared with an ED discharge home with no AKI, an ED discharge 
home with AKI will be associated with a higher risk of all-cause mortality by the 
presence of CKD.54,55 
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Chapter 4  
4 Methods 
 
4.1 Study Design and Setting 
We conducted a population-based, retrospective cohort study of adults 40 years and older 
from June 1, 2003 to March 31, 2012 in Southwestern Ontario, Canada at the Institute for 
Clinical Evaluative Sciences (ICES) Western facility. Southwestern Ontario has 
approximately 1.6 million residents with universal access to hospital care and physician 
services through the Ontario Health Insurance Plan (OHIP).56 Universal prescription drug 
coverage is available for adults 65 years and older through the Ontario Drug Benefit 
(ODB) program. Ontario’s linked health administrative databases provide research 
studies with rich information, large sample sizes, and complete short- and long-term 
follow-up. This study followed the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines for reporting observational studies (Appendix 
B).57 
 
4.2 Ethics 
Our study was approved by the research ethics board at Sunnybrook Health Sciences 
Centre in Toronto, Ontario. Participant informed consent was not required for this study. 
However, to comply with privacy regulations for minimizing the chance of patient re-
identification, results were suppressed in cells with five or fewer patients (reported at ≤5). 
The total number of patients was not reported (NR) if there were other calculations that 
could also result in the re-identification of five or fewer patients. 
 
4.3 Data Sources 
We ascertained patient, ED, and hospital characteristics, prescription drug information, 
and outcome data from 13 health administrative and laboratory databases. These datasets 
were linked using unique, encoded identifiers and analyzed at the ICES Western facility. 
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4.3.1 Administrative Databases 
Ontario Registered Persons Database (RPDB): We obtained patient demographics (age, 
sex, and vital status), income (averaged quintiles of neighbourhood income), and 
residential location (urban vs. rural). Vital statistics are available for all Ontario residents 
who have ever been issued a health card. We used vital statistics information to ascertain 
the outcome of all-cause mortality. 
 
Ontario Drug Benefit (ODB): The ODB database contains records of all outpatient drug 
prescriptions dispensed to residents 65 years and older. Drug prescription accuracy in the 
ODB database is high, with an error rate of less than 1%.58 We used this database to 
obtain baseline medication use for ODB program eligible individuals in the 120 days 
prior to the ED visit date (referred to as the cohort entry or index date) and to determine 
residential status (community-dwelling vs. long-term care). 
 
Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and 
National Ambulatory Care Reporting System (NACRS): We identified diagnostic and 
procedural information on ED visits from NACRS and hospitalizations from CIHI-DAD. 
Diagnostic codes were based on the International Classification of Diseases (ICD), 9th 
revision (ICD-9; pre-2002) and 10th revision (ICD-10; post-2002). Procedural codes 
were derived from the CIHI-DAD Canadian Classification of Health Interventions (CCI), 
Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures (CCP) 
(Appendix C). We also used the CIHI-DAD and NACRS to obtain information on health 
care utilization (Appendix D), application of patient exclusion criteria (Appendix E), and 
health care costs associated with ED visits and hospitalizations (Appendix F). 
 
Ontario Health Insurance Plan (OHIP): The OHIP database contains information on 
physician claims for all health care services (inpatient and outpatient) using fees outlined 
in the OHIP Schedule of Benefits and ICD-9 diagnostic codes. The sensitivity of 
information recorded in the OHIP database is over 90% when procedural codes 
abstracted from the database are compared to the actual code recorded on the chart by the 
physician.59 In addition to diagnostic (ICD-9 and ICD-10) and procedural information 
  
19 
(CCI and CCP) obtained from CIHI-DAD and NACRS, we also used the OHIP database 
to develop our patient exclusion criteria and obtain additional information on baseline co-
morbidities, health care utilization, and outcome variables (Appendix C–F). 
 
Institute for Clinical Evaluative Sciences Physician Database (IPDB): The IPDB records 
contains demographic, specialty, education, and practice information on all practicing 
physicians in Ontario. We used this database to measure the number of family 
physician/general practitioner, nephrologist, internal medicine, and urologist visits and to 
determine ED physician practicing specialty (emergency medicine, family medicine, and 
other) (Appendix D). 
 
4.3.2 Laboratory Databases 
We used two laboratory databases to obtain outpatient and inpatient test results for 
Ontario residents. 
 
Cerner: Cerner is one of the largest electronic health record vendors in the world 
(Missouri, United States of America).60 Thirteen hospitals in Southwestern Ontario share 
the same electronic health record. The Cerner database contains outpatient, ED, and 
inpatient laboratory results for five blood tests (SCr, sodium, potassium, creatine kinase, 
and glucose) for adults 40 years and older from June 1, 2002 and March 31, 2012. We 
used this database to ascertain SCr, sodium, and potassium measurements. 
 
Dynacare Medical Laboratories: The Dynacare database contains outpatient laboratory 
test results from all Dynacare laboratory locations across Ontario since 2002. Dynacare is 
one of the three largest laboratory providers in Ontario, contains records on over 59 
million tests each year, and represents approximately one-third of all Ontario residents.61 
Dynacare does not represent testing in the ED or hospital. We used Dynacare to ascertain 
outpatient SCr and urine protein measurements (albumin, total protein, and dipstick) to 
define baseline kidney function and outcome variables (Appendix F). 
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Due to the inherent limitations of these two databases, this cohort study was restricted to 
patients 40 years and older who visited a Southwestern Ontario hospital equipped with 
the Cerner electronic health record and used Dynacare Medical Laboratories for 
outpatient testing. 
 
4.3.3 Databases for Health Care Cost Estimation 
We used six data sources in addition to the CIHI-DAD, NACRS, OHIP, and ODB 
databases to estimate total health care costs incurred by Ontario residents.62 
 
Assistive Device Program (ADP): The ADP database is operated by the Ministry of 
Health and Long-Term Care and records information on consumer-centered support to 
Ontario residents with long-term disabilities such as personalized assistive devices. 
 
Client Agency Program Enrolment (CAPE): The CAPE database accounts for the 
services provided by multidisciplinary family health teams comprised of family 
physicians, nurses, and other allied health care professionals. 
 
Continuing Care Reporting System (CCRS): The CCRS for chronic care database records 
clinical and demographic information on residents receiving facility-based continuing 
care services, including hospital-based continuing care (complex continuing care, 
extended/chronic care) and residential care providing 24-hour nursing services (nursing 
home, home for the aged). 
 
Home Care Database (HCD): The HCD is derived from either the Ontario Association of 
Community Care Access Centres or the Ministry of Health and records information on 
individuals requiring any home care service provided by the province’s Community Care 
Access Centres. 
 
National Rehabilitation Reporting System (NRS): The NRS database collects, processes, 
and analyzes adult inpatient rehabilitation services at the hospital, regional, and 
provincial/territorial levels. 
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Ontario Mental Health Reporting System (OMHRS): The OMHRS database collects data 
on patients in adult designated inpatient mental health beds, which includes beds in 
General, Provincial Psychiatric, and Specialty Psychiatric facilities. 
 
4.4 Patients 
4.4.1 Inclusion Criteria 
We established a cohort of Ontario adults 40 years and older who visited an ED for any 
reason and had at least one SCr measurement at the ED visit between June 1, 2003 and 
March 31, 2012. The date of the ED visit served as the cohort entry or index date. 
 
4.4.2 Exclusion Criteria 
Before matching (Chapter 4.7), we excluded the following patients from the cohort who: 
(1) died on arrival or during the ED visit, (2) did not have a SCr measurement 7 to 365 
days prior to the ED visit (pre-ED visit baseline) as a baseline SCr measurement was 
needed to diagnose AKI in the ED, (3) received dialysis one year prior to the ED visit as 
AKI would not be relevant on dialysis and to ensure stable kidney function after the 
discontinuation of dialysis, (4) received a kidney transplant in the five years prior to the 
ED visit to ensure AKI was not related to transplant rejection, (5) spent more than 48 
hours in the ED to exclude those without a disposition plan, (6) left against medical 
advice or without being seen by an ED physician, (7) were transferred to another facility, 
or (8) received palliative care 30 days prior to or 14 days after the ED visit to exclude 
those who did not receive active medical management. 
 
4.4.3 Main Cohort and Referent Groups 
Following the application of our inclusion and exclusion criteria, patients were assigned 
to one of three groups based on AKI and ED disposition. The main cohort was a group of 
patients discharged home from the ED with AKI (Figure 5-1). The two referent ED 
groups were patients (1) admitted to hospital from the ED with AKI (Figure 5-2) and (2) 
discharged home from the ED with no AKI (Figure 5-3). 
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For all ED visits with AKI, we excluded patients with an improvement in AKI severity 
during the ED visit. For an ED discharge home with AKI, we excluded those assigned a 
main ED diagnosis of AKI (ICD-10 code: N17) to concentrate on patients less likely to 
be treated and resolved prior to discharge home. For ED visits with no AKI, we selected 
the first ED visit in which the individual had both ED and pre-ED visit baseline SCr 
measurements. 
 
If an individual had multiple ED SCr measurements, we selected the highest value. If 
multiple pre-ED visit baseline SCr values were available, we selected the most recent one 
prior to the ED visit. Pre-ED visit baseline SCr measurements were chosen no earlier 
than seven days prior to the ED visit to avoid potentially unstable baseline values that 
may occur prior to an acute illness. There was no crossover of patients between groups. 
Preference was given to the group discharged home from the ED with AKI if patients 
were also eligible for one of the other two groups. 
 
4.5 Characteristics 
4.5.1 Baseline Characteristics 
We considered several patient demographics, co-morbid conditions, medication use in 
ODB eligible patients, prior health care utilization, pre-ED visit baseline kidney function, 
and ED visit patient and facility characteristics as baseline characteristics in this study 
(Appendix G). We assessed baseline co-morbid conditions in the five years prior to the 
index date.  
 
For ODB program eligible patients, we assessed medication use in the 120 days prior to 
the index date. We evaluated prior health care use including ED or hospital visits, 
physician visits, and diagnostic or screening tests conducted in the previous 365 days. 
 
We used the Charlson co-morbidity index and Aggregated Diagnosis Groups (ADG) 
point score to measure the burden of co-morbidity in our patient population. The 
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Charlson co-morbidity index is based on the International Classification of Diseases 
diagnosis codes found in administrative data.63 Derived from the Charlson score, the 
metric measures the general co-morbidity based on the relative effects of a combination 
of diseases or risk factors on outcomes for a given individual to show the expected one-
year mortality.64 The ADG point score, derived from the John Hopkins Adjusted Clinical 
Groups® system,65,66 is a weighted measure of health care utilization as a proxy measure 
for co-morbidity and accounts for the duration of condition, severity of condition, 
diagnostic certainty, etiology of the condition, and specialty care involvement. 
 
4.6 Kidney Function 
4.6.1 Acute Kidney Injury 
Acute kidney injury was defined as a relative increase in SCr by 50% or more, or an 
absolute increase in a SCr value of 26.5 µmol/L or more, from the most recent pre-ED 
visit baseline SCr. We adapted the 2012 KDIGO guidelines to identify and stage patients 
according to AKI severity.14 Stage 1 AKI was defined as evidence of a relative increase 
in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2 AKI: evidence of 
a relative increase in SCr value of ≥100% to <200% from baseline; and stage 3 AKI: 
evidence of a relative increase in SCr value of >200% from baseline or an increase in SCr 
value to ≥354 µmol/L or the initiation of renal replacement therapy. Urine output was not 
available in our data sources. 
 
We defined AKI using SCr measurements because our group showed that the ICD-10 
diagnostic code N17 demonstrated poor sensitivity in the identification of AKI in ED 
setting (7-30%).41 Validation of the AKI code in a subset of patients discharged home 
from the ED with AKI is unknown and may demonstrate even lower sensitivities. 
Reliance of ICD-10 diagnostic codes would likely result in the exclusion of many 
patients who truly had AKI, as well as falsely identifying some patients as not having 
AKI when they in fact had AKI. 
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4.6.2 Baseline Kidney Function 
We used pre-ED visit SCr measurements to assess baseline kidney function and used the 
CKD-EPI equation to calculate the eGFR.12 All eGFR values were reported in 
mL/min/1.73m2. CKD was defined as an eGFR<60.67 We also stratified baseline kidney 
function into the following groups: normal renal function, stage 1 or 2: eGFR≥60 
mL/min/1.72m2, stage 3a: 45≤eGFR<60, stage 3b: 30≤eGFR<45, stage 4 or 5: eGFR<30 
but not on dialysis. Patients with an eGFR 15 to <30 were combined with patients with an 
eGFR <15 to comply with ICES privacy regulations on reporting small numbers. 
 
4.7 Propensity Score Matching 
To provide context for our primary and secondary outcome (Chapter 4.8), we conducted 
two separate propensity score matching analyses. In the first matching study, we 
compared patients discharged home from the ED with AKI to patients admitted to 
hospital from the ED with AKI (referred to as the AKI subpopulation). In the second 
matching study, we compared patients discharged home from the ED with AKI to 
patients discharged home from the ED with no AKI (referred to as the discharged 
subpopulation). 
 
We used propensity scores to achieve balance on measured baseline characteristics and 
eliminate systematic differences between comparison groups of each matching study 
(Appendix G).68–71 Propensity score is defined as the probability (“propensity”) of an 
exposure, treatment, or intervention for an individual given a set of measured, relevant 
characteristics.70,71 Propensity scores are often estimated using a multivariable logistic 
regression model. Individuals are then matched based on the same or similar propensity 
scores,72 which is described in Chapters 4.7.1 and 4.7.2. 
 
4.7.1 AKI Subpopulation 
We formed a matched set of ED patients with AKI in two groups with a similar ED 
disposition probability (discharged home vs. admission to hospital) for a given set of 
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baseline covariates.68–71 We estimated propensity scores using a multivariable logistic 
regression model with 92 baseline characteristics selected because of potential influence 
on outcomes between comparison groups (Appendix G).71,73,74 We matched one ED 
patient discharged home with AKI (comparison group) to one ED patient admitted to 
hospital with AKI (referent group) on the logit of the propensity score [with a specified 
caliper width of ± 0.2 times the standard deviation (SD)] and AKI stage (1, 2, or 3).72 
Several matching techniques are available, including individual versus frequency 
matching,70 and greedy versus optimal matching.71 The implementation of greedy 
matching is simple, straightforward, and efficient in studies involving large health care 
administrative databases and performs as well as optimal matching in forming balanced 
groups.75 For these reasons, we selected the greedy matching technique. One ED patient 
discharged home with AKI was first selected at random to the nearest patient admitted to 
hospital with AKI within the specified caliper distance, even if there was a better match 
for a subsequent ED patient discharged home with AKI.71 The process was repeated for 
ED patents with AKI until patients admitted to hospital had been matched to ED patients 
discharged home, or until the list of patients discharged home for whom a matched 
patient admitted to hospital could be found had been exhausted. Patients were matched 
without replacement and those who were not matched successfully were excluded from 
the analysis. 
 
4.7.2 Discharged Subpopulation 
We formed a matched set of ED patients discharged home in two groups with a similar 
probability of having AKI for a given set of baseline covariates.68–71 We estimated 
propensity scores using a multivariable logistic regression model with 91 baseline 
characteristics (Appendix G).71,73,74 We matched one ED patient discharged home with 
AKI (comparison group) to one ED patient discharged home with no AKI (referent 
group) on the logit of the propensity score (with a specified caliper width of ± 0.2 times 
the SD) and CKD stage using eGFR categories: ≥60 mL/min/1.72m2, 45≤eGFR<60; 
30≤eGFR<45, 15≤eGFR<30, and an eGFR<15, but not on dialysis. We used the same 
matching techniques and preferences described for the AKI subpopulation. 
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4.7.3 Incomplete or Missing Data 
Information on medication use was not be available in patients under 65 years of age as 
they are not eligible for universal drug coverage through the ODB program. A large 
proportion of ED patients discharged home with AKI would be excluded from the 
analysis had we restricted our cohort to individuals 65 years and older. However, our 
propensity score includes ODB program eligibility and several co-morbid conditions for 
which these missing medications would be indicated. For these reasons, we included ED 
patients with AKI regardless of age and accepted the limitations associated with missing 
medication information in patients under 65 years of age. 
 
We anticipated all baseline characteristics to be complete with a few exceptions. First, 
income quintile was expected to be missing in less than 2% of patients.41,76,77 Second, 
location of residence was expected to be missing in up to 0.2%.78 To account for 
incomplete or missing data before matching, we imputed ‘no’ for missing rural residency 
status and the middle quintile for missing income (income quintile 3). We also imputed 
the median value for missing serum sodium and potassium concentrations.79 The 
proportion of missing serum sodium and potassium concentrations was expected to be 
low because physicians routinely request serum sodium, potassium, and creatinine 
collectively in a panel of tests. 
 
4.8 Outcomes 
4.8.1 Primary Outcome 
The primary outcome for all analyses was all-cause mortality. We restricted our analysis 
to 30 days after the index date, which is an acceptable timeframe to attribute an outcome 
to the ED visit.80 All-cause mortality was obtained from vital statistics in the RPDB. The 
mortality flag in the RPDB has a sensitivity of 94% and a positive predictive value of 
100%.81 
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4.8.2 Secondary Outcome 
The secondary outcome for all analyses was the receipt of hospital-based acute dialysis. 
We restricted our analysis to 30 days after the index date. Physicians report billing and 
procedural codes related to the initiation of hospital-based acute dialysis. Dialysis billing 
and procedural codes in the setting of AKI have a specificity of greater than 94% (median 
99%).82 
 
4.8.3 Additional Outcomes 
As outlined in Chapter 3.2.1.2, we assessed five additional outcomes for the main cohort 
of patients discharged from the ED with AKI. We did not assess these outcomes for the 
two propensity score matching analyses. The five additional outcomes were (1) 
hospitalization after an ED discharge home, (2) at least one outpatient physician visit 
(family physician, internist, nephrologist, or urologist), (3) at least one outpatient SCr 
test, (5) at least one outpatient urine test for protein, and (5) total health care costs 
(Appendix F). We restricted our analysis to 30 days after the index date for all five 
additional outcomes. We used an ICES macro to estimate total health care cost associated 
with health care use (Appendix F).62 Cost was reported in Canadian dollars and adjusted 
for inflation to the year 2013. 
 
4.9 Statistical Analyses 
4.9.1 All Analyses 
We compared baseline characteristics using standardized differences. This metric 
compares two group means relative to a pooled standard deviation. A standardized 
difference of 10% or greater is considered meaningful,83 and it is preferred over 
hypothesis testing (using P values) for large samples because it is not influenced by 
sample size.84–86 In propensity score matching studies with large groups, one can compare 
balance in characteristics in both an unmatched and matched sample.85,86  
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4.9.2 AKI Subpopulation 
We estimated propensity scores using 92 baseline characteristics (Appendix G). SCr at 
ED visit and AKI stage were variables in the propensity score specific to the AKI 
subpopulation. ED length of stay was not included because it is dependent on when the 
patient physically leaves the ED. The transfer of care from the ED physician to an 
admitting service may have occurred several hours before the patient was physically 
moved to a hospital bed. Therefore, ED length of stay will always differ between these 
two groups. 
 
We estimated the relative risk (RR) and 95% confidence intervals (CI) for our primary 
and secondary outcome using a modified Poisson regression model that accounted for 
matched data.87,88 Compared to the odds ratio, the RR is a more intuitive measure of 
effect and does not overestimate risk with increasing frequency of the outcome.89 Patients 
admitted to hospital from the ED with AKI served as the referent group. We also 
evaluated the association between ED disposition (discharge home vs. admission to 
hospital) and our primary outcome in a pre-specified subgroup defined by AKI stage 
(Chapter 4.6.1).14 We determined interaction P values by including interaction terms in 
the modified Poisson regression model. 
 
4.9.3 Discharged Subpopulation 
We estimated propensity scores with 91 baseline characteristics, 90 of which were 
identical to those used in the AKI subpopulation (Appendix G). ED length of stay was a 
variable in the propensity score specific to the discharged subpopulation. Because this 
analysis compared patients with AKI versus no AKI, SCr at ED visit and AKI stage were 
not included in the propensity score. 
 
We estimated the RR and 95% CI for our outcomes using a modified Poisson regression 
model that accounted for matched data.87,88 Patients discharged home from the ED with 
no AKI served as the referent group. We also evaluated the association between AKI and 
our primary outcome in a pre-specified subgroup defined by CKD stage (Chapter 
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4.6.2).67 We determined interaction P values by including interaction terms in the 
modified Poisson regression model. 
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Chapter 5  
5 Results 
 
5.1 Descriptive Analysis 
5.1.1 Characteristics of Patients Discharged Home from the 
Emergency Department with Acute Kidney Injury 
There were 6346 patients discharged home from the ED with AKI included in the cohort 
over a 10-year period (Figure 5-1 and Table 5-1). Among these patients, 6012 (94.7%) 
had stage 1, 290 (5.2%) had stage 2, and 44 (0.7%) had stage 3 AKI. The mean (SD) age 
was 69 (14) years, 46.5% were female, and 15.3% lived in a rural residence. The most 
common pre-existing co-morbidities were hypertension (75.4%), CKD (38.2%), diabetes 
(37.9%), coronary artery disease (34.0%), heart failure (~21.7%), and major cancer 
(16.6%). There were 4605 (72.6%) patients with universal drug coverage through the 
ODB program and they were prescribed a median of five medications in the 120 days 
prior to the ED visit. The most commonly prescribed medications were angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers (59.7%), non-potassium 
sparing diuretics (56.7%), statins (47.2%), antibiotics (44.3%), beta-adrenergic 
antagonists (38.7%), and proton pump inhibitors (35.9%). Non-steroidal anti-
inflammatory drugs were prescribed in 19.4% of patients. 
 
Before the index date, there were 1114 (17.6%) patients in the previous 30 days and 3624 
(57.1%) patients in the previous 31 to 365 days who had at least one ED visit. There were 
481 (7.6%) patients in the previous 30 days and 1933 (30.5%) patients in the previous 31 
to 365 days who required at least one hospitalization. In the 365 days before the index 
date, 98.5% of patients had at least one family physician visit. Outpatient clinic visits 
with a general internist (23.2%), nephrologist (~4.6%), and urologist (17.8%) were less 
common. The most frequently ordered diagnostic test, procedure, or intervention in the 
previous 365 days was an abdominal ultrasound (24.1%). The median [interquartile range 
(IQR)] pre-ED visit baseline SCr concentration was 87 (71-112) µmol/L and was 
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measured a median (IQR) 106 (44-207) days prior to the index date. A urine albumin-to-
creatinine ratio (ACR) was measured in 26.6% of patients with approximately 10% 
having micro- or macroalbuminuria. 
 
During the index ED visit, the majority (80.6%) of patients were assigned to urgent or 
emergent triage acuity scores [Canadian Triage Acuity Scale (CTAS) 1 to 3]. The 90th 
percentile for ED length of stay was 8 to 9 hours. The median (IQR) ED SCr 
concentration was 129 (109-162) µmol/L. The three most frequent main diagnoses 
assigned by ED physicians were throat or chest pain (8.1%), abdominal or pelvic pain 
(7.0%), and renal colic (4.9%) (Appendix H). 
 
Income quintile was not available for 99 (1.6%) patients. Serum potassium and sodium, 
both measured in a panel of electrolytes, were not available for 492 (7.8%) patients. 
 
5.1.2 Characteristics by Acute Kidney Injury Severity 
Cohort characteristics by AKI stage are shown in Table 5-1. Consistent with the 
diagnostic criteria for AKI, ED visit SCr concentrations increased with AKI stage. 
Compared to patients with stage 1 AKI, patients with stage 2 AKI were more likely to be 
female, have lower income, reside in long-term care, have dementia, be prescribed 
immunosuppressive medications and potassium-sparing diuretics, and have lower pre-ED 
visit baseline SCr concentrations. They were less likely to have coronary artery disease, 
CKD, and heart failure, be prescribed beta-adrenergic antagonists, oral hypoglycemic 
agents or insulin, and xanthine oxidase inhibitors or uricosuric agents, be seen by a 
urologist, have cardiac imaging, and be assigned an emergent triage acuity level (CTAS 1 
or 2). 
 
Compared to patients with stage 1 AKI, patients with stage 3 AKI were younger and 
more likely to be female, have higher income, hypertension, major cancer, and an 
Aggregated Diagnosis Group (ADG) point score of ≥6. Although these patients were 
prescribed fewer medications in the previous 120 days, they were more likely to be 
prescribed antibiotics, antidepressants, non-potassium sparing diuretics, non-steroidal 
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anti-inflammatory drugs, and proton pump inhibitors. There were also more likely to 
have a remote pre-ED visit baseline SCr measurement, lower serum sodium 
concentration, require hospitalization in the previous 30 days, have a previous abdominal 
ultrasound, and be assigned a less urgent triage acuity level (CTAS 4 or 5). They were 
less likely to have coronary artery disease, dementia, and diabetes, be prescribed calcium 
channel blockers, oral hypoglycemic agents or insulin, and statins, have an ED visit or 
hospitalization in the previous 31 to 365 days, be seen at least once by a family physician, 
and be assigned a CTAS of 1 or 2. 
 
Compared to patients with stage 2 AKI, patients with stage 3 AKI were younger and 
more likely to have higher income, hypertension, a Charlson co-morbidity index of ≥3, 
and an ADG point score of ≥6. Although these patients were prescribed fewer 
medications in the previous 120 days, they were more likely to be prescribed antibiotics, 
antidepressants, beta-adrenergic antagonists, non-steroidal anti-inflammatory drugs, and 
proton pump inhibitors, have a higher pre-ED visit baseline SCr concentration, higher ED 
serum potassium concentration, lower ED serum sodium concentration, have a previous 
abdominal ultrasound, require hospitalization in the previous 30 days, be seen at least 
once by a urologist, and be assigned a CTAS of 4 or 5. They were less likely to live in a 
rural residence, have dementia and diabetes, be prescribed calcium channel blockers, 
corticosteroids, and statins, have an ED visit or hospitalization in the previous 31 to 365 
days, be seen at least once by a family physician, and be assigned a CTAS of 3.  
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Figure 5-1: Selection of Cohort of Patients Discharged Home from the Emergency 
Department with Acute Kidney Injury from 2003 to 2012 
 
Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases; 
SCr serum creatinine. 
a Patients were excluded in order as listed. 
b We selected the most recent pre-ED visit baseline SCr measurement. 
c If an individual had more than one ED visit with AKI, we selected the first ED visit. 
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Table 5-1: Baseline Characteristics of Patients Discharged Home from the Emergency Department with Acute Kidney Injury 
 Number of patients, n (%)a 
 All patients AKI stage
b 
 1 2 3 
Cohort size  6346 6012 290 44 
Demographics     
Age, in years     
    Mean (SD) 69 (14) 69 (13) 68 (14) 65 (13)‡§ 
    Median (IQR) 70 (58-79) 70 (58-79) 70 (57-79) 62 (58-77) 
    40 to <65 2326 (36.7) 2189 (36.4) 112 (38.6) 25 (56.8)‡§ 
    65 to <80 2475 (39.0) 2351 (39.1) 114 (39.3) 10 (22.7)‡§ 
    ≥80 1545 (24.3) 1472 (24.5) 64 (22.1) 9 (20.5) 
Sex, female 2948 (46.5) 2745 (45.7) 177 (61.0)† 26 (59.1)‡ 
Year of cohort entry     
    2003 to 2005 1593 (25.1) 1497 (24.9) 87 (30.0)† 9 (20.5)‡§ 
    2006 to 2008 2903 (45.7) 2769 (46.1) 116 (40.0)† 18 (40.9)‡ 
    2009 to 2011 1850 (29.2) 1746 (29.0) 87 (30.0) 17 (38.6)‡§ 
Rural residence 969 (15.3) 912 (15.2) 51 (17.6) 6 (13.6)§ 
Neighbourhood income quintile     
    1 1401 (22.1) 1314 (21.9) 78 (26.9)† 9 (20.5)§ 
    2 1353 (21.3) 1290 (21.5) 54 (18.6) 9 (20.5) 
    3 1307 (20.6) 1238 (20.6) 62 (21.4) 7 (15.9)‡§ 
    4 1046 (16.5) 996 (16.6) 42 (14.5) 8 (18.2)§ 
    5 1140 (18.0) 1079 (17.9) 50 (17.2) 11 (25.0)‡§ 
Pharmacy forward sortation areac 5214 (82.2) 4945 (82.3) 233 (80.3) 36 (81.8) 
 
Co-morbid conditionsd     
Abdominal aortic aneurysm repair 48 (0.8) 37 (0.8) ≤5 (≤1.7) ≤5 (≤11.4)‡ 
Atrial fibrillation or flutter NR 627 (10.4) 23 (7.9) ≤5 (≤11.4)‡ 
Cerebrovascular disease NR 243 (4.0) 14 (4.8) ≤5 (≤11.4)‡§ 
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Chronic liver disease NR 399 (6.6) 24 (8.3) ≤5 (≤11.4)§ 
Chronic obstructive pulmonary disease NR 369 (6.1) 22 (7.6) ≤5 (≤11.4)‡§ 
Coronary artery diseasee 2160 (34.0) 2069 (34.4) 78 (26.9)† 13 (29.5)‡ 
Dementia NR 591 (9.8) 39 (13.4)† ≤5 (≤11.4)‡§ 
Diabetes 2405 (37.9) 2292 (38.1) 100 (34.5) 13 (29.5)‡§ 
Heart failure NR 1325 (22.0) 48 (16.6)† ≤5 (≤11.4)‡§ 
Hypertension 4783 (75.4) 4525 (75.3) 222 (76.6) 36 (81.8)‡§ 
Major cancerf 1056 (16.6) 994 (16.5) 53 (18.3) 9 (20.5)‡ 
Nephrolithiasis NR 162 (2.7) 11(3.8) ≤5 (≤11.4)‡§ 
Osteoarthritis NR 431 (7.2) 26 (9.0) ≤5 (≤11.4)‡§ 
Parkinson's disease NR 32 (0.5) ≤5 (≤1.7) ≤5 (≤11.4)‡§ 
Peripheral vascular disease NR 178 (3.0) ≤5 (≤1.7) ≤5 (≤11.4) 
Rheumatoid arthritis NR 429 (7.1) 22 (7.6) ≤5 (≤11.4) 
Charlson co-morbidity indexg     
    0 4181 (65.9) 3962 (65.9) 188 (64.8) 31 (70.5)§ 
    1 NR 661 (11.0) 33 (11.4) ≤5 (≤11.4) 
    2 NR 606 (10.1) 35 (12.1) ≤5 (≤11.4)‡§ 
    ≥3 824 (13.0) 783 (13.0) 34 (11.7) 7 (15.9)§ 
Aggregated Diagnosis Groups scoreh     
    0-5  1757 (27.7) 1669 (27.8) 79 (27.2) 9 (20.5)‡§ 
    ≥6 4589 (72.3) 4343 (72.2) 211 (72.8) 35 (79.5)‡§ 
     
Medication utilizationi     
ODB program eligible patients 4605 (72.6) 4367 (72.6) 213 (73.4) 25 (56.8)‡§ 
    Patients in long-term carej NR 171/4367 (3.9) 13/213 (6.1)† ≤5/25 (≤20.0)‡ 
Medication classk     
    Angiotensin-converting enzyme inhibitor or  
      angiotensin receptor blocker 
2750/4605 (59.7) 2614/4367 (59.9) 122/213 (57.3) 14/25 (56.0) 
    Alpha-1-adrenoceptor antagonist or 
      5-alpha-reductase inhibitor 
NR 279/4367 (6.4) 13/213 (6.1) ≤5/25 (≤20.0) 
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    Anti-retroviral NR 7/4367 (0.2) ≤5/213 (≤2.3) ≤5/25 (≤20.0) 
    Antibiotic 2041/4605 (44.3) 1931/4367 (44.2) 97/213 (45.5) 13/25 (52.0)‡§ 
    Anticoagulant NR 689/4367 (15.8) 32/213 (15.0) ≤5/25 (≤20.0) 
    Antidepressant (SSRI or SNRI) 774/4605 (16.8) 728/4367 (16.7) 40/213 (18.8) 6/25 (24.0)‡§ 
    Antineoplastic (chemotherapy) NR 108/4367 (2.5) ≤5/213 (≤2.3) ≤5/25 (≤20.0)‡§ 
    Antiplatelet NR 714/4367 (16.3) 31/213 (14.6) ≤5/25 (≤20.0)‡§ 
    Antipsychotic NR 284/4367 (6.5) 18/213 (8.5) ≤5/25 (≤20.0) 
    Beta-adrenergic antagonist 1781/4605 (38.7) 1705/4367 (39.0) 66/213 (31.0)† 10/25 (40.0)§ 
    Calcium channel blocker NR 1499/4367 (34.3) 64/213 (30.0) ≤5/25 (≤20.0)‡§ 
    Corticosteroid 1188/4605 (25.8) 1119/4367 (25.6) 63/213 (29.3) 6/25 (24.0)§ 
    Immunosuppressive medication NR 166/4367 (3.8) 13/213 (6.1)† ≤5/25 ≤20.0) 
    Lithium NR 30/4367 (0.7) ≤5/213 (≤2.3)† ≤5/25 ≤20.0)‡ 
    Non-potassium sparing diuretic 2609/4605 (56.7) 2465/4367 (56.4) 128/213 (60.1) 16/25 (64.0)‡ 
    Non-steroidal anti-inflammatory drugl 892/4605 (19.4) 849/4367 (19.4) 34/213 (16.0) 9/25 (36.0)‡§ 
    Oral hypoglycemic agent or insulin NR 1346/4367 (30.8) 52/213 (24.4)† ≤5/25 (≤20.0)‡§ 
    Potassium-sparing diuretic NR 511/4367 (11.7) 34/213 (16.0)† ≤5/25 (≤20.0)‡§ 
    Proton pump inhibitor 1651/4605 (35.9) 1571/4367 (36.0) 68/213 (31.9) 12/25 (48.0)‡§ 
    Statin 2174/4605 (47.2) 2072/4367 (47.4) 93/213 (43.7) 9/25 (36.0)‡§ 
    Xanthine oxidase inhibitor or uricosuric agent NR 302/4367 (6.9) ≤5/213 (≤2.3)† ≤5/25 (≤20.0)‡§ 
Unique drug names 
    Mean (SD) 
 
6 (6) 
 
6 (6) 
 
6 (6) 
 
3 (5)‡§ 
    Median (IQR) 5 (0-10) 5 (0-10) 5 (0-10) 0 (0-7) 
Unique drug identification numbers     
    Mean (SD) 6 (6) 6 (6) 6 (7) 4 (6)‡§ 
    Median (IQR) 5 (0-10) 5 (0-10) 5 (0-10) 0 (0-7) 
     
Pre-ED visit baseline kidney functionm     
Baseline SCr, in µmol/L 
    Mean (SD) 
 
101 (55) 
 
102 (56) 
 
76 (30)† 
 
96 (88)§ 
    Median (IQR) 87 (71-112) 88 (72-112) 71 (56-87) 75 (57-88) 
Days baseline SCr measured pre-ED visit     
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    Mean (SD) 133 (102) 132 (102) 140 (105) 152 (116)‡§ 
    Median (IQR) 106 (44-207) 106 (44-206) 126 (45-215) 115 (46-256) 
Baseline SCr ≤50 µmol/L NR 215 (3.6) 44 (15.2)† ≤5 (≤11.4)‡§ 
Baseline eGFR     
    ≥60 ml/min/1.73m2 3919 (61.8) 3654 (60.8) 230 (79.3)† 35 (79.5)‡ 
    45 to <60 ml/min/1.73m2 NR 1029 (17.1) 34 (11.7)† ≤5 (≤11.4)‡§ 
    30 to <45 ml/min/1.73m2 NR 833 (13.9) 19 (6.6)† ≤5 (≤11.4)‡ 
    <30 ml/min/1.73m2 NR 496 (8.3) 7 (2.4)† ≤5 (≤11.4)§ 
CKD risk categoryn     
    Low risk NR 678 (11.3) 41 (14.1) ≤5 (≤11.4) 
    Moderate risk NR 293 (4.9) 15 (5.2) ≤5 (≤11.4)‡§ 
    High risk NR 366 (6.1) 16 (5.5) ≤5 (≤11.4) 
    Very high risk NR 654 (10.9) 12 (4.1)† ≤5 (≤11.4)§ 
Urine ACR measured 1689 (26.6) 1602 (26.6) 77 (26.6) 10 (22.7) 
    <30 mg/mmol NR 959 (16.0) 49 (16.9) ≤5 (≤11.4)‡§ 
    30 to <300 mg/mmol NR 262 (4.4) 13 (4.5) ≤5 (≤11.4) 
    ≥300 mg/mmol NR 381 (6.3) 15 (5.2) ≤5 (≤11.4) 
     
ED visit laboratory values     
Serum potassium, in mmol/L 
    Mean (SD) 4.2 (0.6) 4.2 (0.6) 4.1 (0.8)† 4.2 (0.8)§ 
    Median (IQR) 4.1 (3.8-4.5) 4.1 (3.8-4.5) 4.1 (3.6-4.5) 4.2 (3.6-4.8) 
Serum sodium, in mmol/L     
    Mean (SD) 137 (5) 137 (5) 136 (5)† 134 (5)‡§ 
    Median (IQR) 138 (135-140) 138 (135-140) 137 (134-139) 134 (131-139) 
SCr, in µmol/L     
    Mean (SD) 147 (70)  145 (66) 174 (75)† 335 (182)‡§ 
    Median (IQR) 129 (109-162) 128 (108-159) 159 (128-205) 301 (200-427) 
Absolute change in SCr, in µmol/L     
    Mean (SD) 47 (31) 43 (19) 98 (46)† 239 (122)‡§ 
    Median (IQR) 38 (31-51) 37 (31-48) 88 (68-119) 217 (139-328) 
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Percent change in SCr, in %     
    Mean (SD) 52 (34) 48 (18) 129 (26)† 294 (128)‡§ 
    Median (IQR) 45 (35-60) 44 (34-57) 121 (108-144) 265 (224-359) 
     
Previous health care utilizationo     
ED visit in the previous     
    30 days 1114 (17.6) 1062 (17.7) 45 (15.5) 7 (15.9) 
    31 to 365 days 2510 (39.5) 2384 (39.7) 114 (39.3) 12 (27.3)‡§ 
Hospitalization in the previous     
    30 days 481 (7.6) 451 (7.5) 24 (8.3) 6 (13.6)‡§ 
    31 to 365 days 1452 (22.9) 1366 (22.7) 78 (26.9) 8 (18.2)‡§ 
Outpatient physician visits     
    Family physician 6251 (98.5) 5924 (98.5) 283 (97.6) 44 (70.5)‡§ 
        0 to 4 visits 1069 (16.8) 1017 (16.9) 46 (15.9) 6 (13.6) 
        5 to 10 visits 2287 (36.0) 2161 (35.9) 109 (37.6) 17 (38.6) 
        ≥11 visits 2990 (47.1) 2834 (47.1) 135 (46.6) 21 (47.7) 
    General internist (≥1 visit) 1470 (23.2) 1385 (23.0) 76 (26.2) 9 (20.5)§ 
    Nephrologist (≥1 visit) NR 270 (4.5) 14 (4.8) ≤5 (≤11.4) 
    Urologist (≥1 visit) 1132 (17.8) 1084 (18.0) 40 (13.8)† 8 (18.2)§ 
Diagnostic imaging and procedures     
    Abdominal ultrasoundp 1530 (24.1) 1456 (24.2) 59 (20.3) 15 (34.1)‡§ 
    Cardiac stress test NR 931 (15.5) 34 (11.7)† ≤5 (≤11.4)‡§ 
    Coronary angiogram or  
      revascularization 
NR 138 (2.3) 6 (2.1) ≤5 (≤11.4)‡§ 
    CT scan with contrast NR 175 (2.9) 7 (2.4) ≤5 (≤11.4) 
    Echocardiogram NR 1097 (18.2) 34 (11.7)† ≤5 (≤11.4)‡§ 
    Intervention for kidney stonesq NR 73 (1.2) ≤5 (≤1.7) ≤5 (≤11.4) 
     
ED and hospital characteristics     
Institutionr     
1 1754 (27.6) 1665 (27.7) 78 (26.9) 11 (25.0) 
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2 1482 (23.4) 1400 (23.3) 70 (24.1) 12 (27.3) 
3 NR 608 (10.1) 36 (12.4) ≤5 (≤11.4)‡§ 
4 NR 435 (7.2) 26 (9.0) ≤5 (≤11.4) 
5 NR 145 (2.4) 10 (3.4) ≤5 (≤11.4)‡ 
6 NR 42 (0.7) ≤5 (≤1.7) ≤5 (≤11.4)‡§ 
7 NR 569 (9.5) 35 (12.1) ≤5 (≤11.4) 
8 NR 241 (4.0) 7 (2.4) ≤5 (≤11.4) 
9 NR 338 (5.6) 10 (3.4)† ≤5 (≤11.4)§ 
10 NR 366 (6.1) 10 (3.4)† ≤5 (≤11.4) 
11 NR 148 (2.5) ≤5 (≤1.7) ≤5 (≤11.4)‡§ 
12 NR 32 (0.5) ≤5 (≤1.7) ≤5 (≤11.4)‡§ 
13 NR 23 (0.4) ≤5 (≤1.7) ≤5 (≤11.4) 
ED and hospital activity     
Standardized number of ED registrations 
  in the last 12hs     
    Mean (SD) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 1.0 (0.3)‡§ 
    Median (IQR) 1.1 (0.9-1.3) 1.1 (0.9-1.3) 1.1 (0.9-1.3) 1.0 (0.8-1.3) 
Standardized number of hospital admissions 
  in the last 24ht     
    Mean (SD) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3)‡ 
    Median (IQR) 1.1 (0.8-1.3) 1.1 (0.8-1.3) 1.1 (0.8-1.3) 1.2 (0.9-1.3) 
Standardized number of hospital discharges 
  in the last 24hu     
    Mean (SD) 1.1 (0.4) 1.1 (0.3) 1.1 (0.4) 1.1 (0.4)‡§ 
    Median (IQR) 1.1 (0.8-1.2) 1.1 (0.8-1.2) 1.1 (0.8-1.2) 1.3 (0.9-1.4) 
Standardized proportion of ED registrations  
  resulting in hospitalization, in %v 
47.0 47.0 49.0 48.0 
ED seasonal and time characteristics     
    Time of day     
        0700 to <1700 3320 (52.3) 3128 (52.0) 162 (55.9) 30 (71.1)‡§ 
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        1700 to <2400 2226 (35.1) 2125 (35.3) 91 (31.4) ≥9 (≥20.5)‡§ 
        0000 to <0700 NR 759 (12.6) 37 (12.8) ≤5 (≤11.4)‡§ 
    Seasonw     
        Fall 1502 (23.7) 1418 (23.6) 71 (24.5) 13 (29.5)‡§ 
        Winter 1446 (22.8) 1358 (22.6) 77 (26.6) 11 (25.0) 
        Spring 1635 (25.8) 1563 (26.0) 63 (21.7)† 9 (20.5)‡ 
        Summer 1763 (27.8) 1673 (27.8) 79 (27.2) 11 (25.0) 
    ED physician training     
        Emergency medicine 4642 (73.1) 4403 (73.2) 210 (72.4) 29 (65.9)‡§ 
        Family medicine 1338 (21.1) 1264 (21.0) 62 (21.4) ≥10 (≥22.7)‡§ 
        Other NR 345 (5.7) 18 (6.2) ≤5 (≤11.4) 
     
ED patient acuity and wait times     
CTASx     
    1 or 2 1321 (20.8) 1271 (21.1) 43 (14.8)† 7 (15.9)‡ 
    3 3797 (59.8) 3579 (59.5) 193 (66.6)† 25 (56.8)§ 
    4 or 5 1228 (19.4) 1162 (19.3) 54 (18.6) 12 (27.3)‡§ 
Time (in hours) waiting for physician  
  assessment, mean (SD)     
    CTAS 1 or 2 0.6 (0.8) 0.6 (0.8) 0.5 (0.6)† 0.3 (0.5)‡§ 
    CTAS 3 1.3 (1.3) 1.3 (1.3) 1.5 (1.3) 1.6 (1.1)‡§ 
    CTAS 4 or 5 1.6 (1.4) 1.6 (1.4) 1.7 (1.4) 1.4 (1.2)‡§ 
90% percentile ED length of stay, in hours     
    CTAS 1 or 2 9 9 10 7 
    CTAS 3 9 9 8 10 
    CTAS 4 or 5 8 8 9 8 
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED, 
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ODB: Ontario Drug Benefit; NR, not reported; SCr, serum creatinine; SD, standard 
deviation; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor.  
A standardized difference of ≥10% was found between two AKI stage comparisons: † stage 1 vs. stage 2; ‡ stage 1 vs. stage 3; and § stage 2 vs. stage 3. To convert SCr from SI 
units (µmol) to traditional units (mg/dL), divide by 88.42. 
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a Numbers reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were 
suppressed in the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or 
fewer patients. 
b Stage 1, evidence of a relative increase in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2, evidence of a relative increase in SCr value of ≥100% to <200% 
from baseline; and stage 3, evidence of a relative increase in SCr value of >200% from baseline or an absolute increase in SCr value to ≥354 mg/dL or the initiation of dialysis. 
c Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of 
individuals who live in the same region as the pharmacy that provided them with prescription medications.  
d Look-back window for co-morbidities was five years unless otherwise noted. 
e Does not include angina. 
f Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus. 
g Look-back window for the Charlson co-morbidity index was two years.63,64 
h The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization 
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care 
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG 
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization. 
i Look-back window for medication utilization was 120 days. 
j Patients in long-term care were identified from the ODB database. 
k Percentages reported are based on the number of ODB program eligible patients (age 65 years and older). 
l Does not include acetylsalicylic acid. 
m Pre-ED visit look-back window was 7 to 365 days. 
n CKD risk categories derived from 2012 Kidney Diseases: Improving Global Outcomes guidelines. In addition to using urine ACR measurements, urine dipstick and protein 
values were converted to an estimate urine ACR.67  
o Look-back window for health care utilization was 365 days unless otherwise noted. 
p An abdominal ultrasound is not specific for the assessment of the kidneys. 
q Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal. 
r For privacy considerations, individual hospital institutions were not identified. 
s Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days. 
t Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days. 
u Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days. 
v Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours. 
w Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20. 
x Patients with a Canadian Triage Acuity Scale (CTAS) of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a 
CTAS of 3 or 4 need to be seen within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes 
80% of the time.
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5.1.3 Outcomes 
In the 30 days following an ED discharge home with AKI, 149 (2.3%) patients died, 22 
(0.3%) received hospital-based acute dialysis, and 1032 (16.3%) required hospitalization. 
In the outpatient setting, 4287 (67.6%) were seen by a physician (family physician, 
general internist, nephrologist, or urologist), 1446 (22.8%) had a SCr test, and 12% had a 
urine test for protein (Table 5-2). The median (IQR) 30-day health care cost was $1172 
($661-$3020) dollars. 
 
In the 30 days following an ED discharge home, 127 (2.1%) patients with stage 1, 15 
(5.2%) with stage 2, and 7 (15.9%) with stage 3 AKI died.  There were 956 (15.9%) 
patients with stage 1, 62 (21.4%) with stage 2, and 14 (31.8%) with stage 3 AKI who 
required hospitalization. In the outpatient setting, 4062 (67.6%) patients with stage 1, 197 
(67.9%) with stage 2, and 28 (63.6%) with stage 3 AKI visited a physician and 1339 
(22.8%) patients with stage 1, 89 (30.7%) with stage 2, and 18 (40.9%) with stage 3 AKI 
had a SCr measurement. Mean and median health care costs appeared to increase with 
AKI severity.
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Table 5-2: Thirty-Day Outcomes of Patients Discharged Home from the Emergency Department with Acute Kidney Injury 
Outcome 
Number of patients, n (%)a 
All patients 
(N=6346) 
AKI stageb 
1 (N=6012) 2 (N=290) 3 (N=44) 
Primary Outcome     
All-cause mortality 149 (2.3) 127 (2.1) 15 (5.2) 7 (15.9) 
     
Secondary Outcome     
Receipt of hospital-based acute  
  dialysis 
22 (0.3) NR ≤5 (≤1.7) ≤5 (≤11.4) 
     
Additional Outcomes     
At least one hospitalization 1032 (16.3) 956 (15.9) 62 (21.4) 14 (31.8) 
At least one outpatient:     
    Physician clinic visitc 4287 (67.6) 4062 (67.6) 197 (67.9) 28 (63.6) 
    SCr test 1446 (22.8) 1339 (22.3) 89 (30.7) 18 (40.9) 
    Urine test for proteind NR 713 (11.9) 41 (14.1) ≤5 (≤11.4) 
Total health care costse     
    Mean (SD) $3522 ($7079) $3499 ($7135) $3856 ($6065) $4429 ($5454) 
    Median (IQR) $1172 ($661-3020) $1164 ($657-2955) $1342 ($749-4372) $1748 ($699-6478) 
Abbreviations: AKI, acute kidney injury; IQR, interquartile range; NR, not reported; SCr, serum creatinine; SD, standard deviation. 
a Reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in the 
case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients. 
b AKI stage 1, evidence of a relative increase in SCr value of ≥50% to <100% or ≥26.5 µmol/L from baseline; stage 2, evidence of a relative increase in SCr value of ≥100% to 
<200% from baseline; and stage 3, evidence of a relative increase in SCr value of >200% from baseline or an absolute increase in SCr value to ≥354 µmol/L or the initiation of 
dialysis.14 
c Outpatient physician specialties included any one of: family medicine, internal medicine, nephrology, or urology. 
d Tests for urine protein included any one of: dipstick, protein, or ACR. 
e Reported in Canadian dollars, adjusted for inflation to 2013. 
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5.2 Propensity Score Matching Analysis 
5.2.1 AKI Subpopulation 
5.2.1.1 Unmatched Cohort 
Cohort selection for the AKI subpopulation is presented in Figure 5-2. Baseline 
characteristics before and after matching are presented in Table 5-3. 
 
Before matching, there were 14,463 patients who visited an ED and had evidence of AKI. 
Among these patients, 6346 were discharged home and 8117 were admitted to hospital. 
Patients discharged home from the ED with AKI as compared to those admitted to 
hospital from the ED with AKI were younger (mean age 69 vs. 73 years) and more likely 
to have a slightly more remote pre-ED visit baseline SCr measurement [mean (median) 
133 (106) vs. 121 (90) days], a slightly lower pre-ED visit baseline SCr concentration 
[mean (median) 101 (87) vs. 115 (96) µmol/L], and a previous urine ACR measurement 
(26.6 vs. 22.1%). In the ED, they were more likely to have a slightly lower serum 
potassium [mean (median) 4.2 (4.1) vs. 4.4 (4.3) mmol/L], slightly higher serum sodium 
concentration [mean (median) 137 (138) vs. 136 (136) mmol/L], lower ED SCr 
concentration [mean (median) 147 (129) vs. 208 (162) µmol/L], stage 1 AKI (94.7 vs. 
78.9%), be assigned a less urgent triage acuity level (CTAS 3: 59.8 vs 52.4%, CTAS 4 or 
5: 19.4 vs. 8.8%), and in patients assigned an urgent or emergent triage acuity level, 
spend more time waiting for a physician assessment (CTAS 1 or 2: 0.8 vs. 0.6 hours, 
CTAS 3: 1.3 vs. 1.2 hours). 
 
These patients had fewer co-morbidities (coronary artery disease: 34.0 vs. 38.5%, CKD: 
38.2 vs. 51.9%, diabetes: 37.9 vs. 43.1%, hypertension: 75.4 vs. 79.5%, major cancer: 
16.6 vs. 21.4%, Charlson co-morbidity index of ≥3: 13.0 vs. 20.4%, and ADG point score 
of ≥6: 72.3 vs. 76.7%), and were less likely to have universal drug coverage (72.6 vs. 
83.1%), be prescribed non-potassium sparing diuretics (56.7 vs. 62.4%), have stage 2 or 3 
AKI (5.3 vs. 21.1%), require hospitalization in the previous 365 days (30.5 vs. 43.3%), be 
seen by a family physician ≥11 times in the past year (47.1 vs. 53.1%), be seen at least 
once by a general internist (23.2 vs. 30.6%), be seen in the ED during daytime (52.3 vs. 
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71.5%) and overnight hours (12.6 vs. 17.1%), and be assigned an emergent triage acuity 
level (CTAS 1 or 2: 20.8 vs. 38.7%). 
 
There was no difference in female sex, rural residence, income, abdominal aortic 
aneurysm repair, cerebrovascular disease, chronic liver disease, coronary artery disease, 
nephrolithiasis, osteoarthritis, Parkinson’s disease, peripheral vascular disease, 
rheumatoid arthritis, use of all medications except non-potassium sparing diuretics, 
proportion of patients with a pre-ED visit baseline SCr ≤50 µmol/L, at least one ED visit 
in the previous 365 days, at least one family physician visit, at least one nephrologist 
visit, at least one urologist visit, abdominal ultrasound, cardiac stress test, coronary 
angiogram or revascularization, intervention for kidney stones, season of the year, and 
two ED physician specialties (Emergency Medicine and Family Medicine). 
 
5.2.1.2 Matched Cohort 
A total of 4379 patients discharged from the ED with AKI were successfully matched to 
4379 patients admitted to hospital from the ED with AKI (Table 5-3). The matched 
cohort comprised of 4091 (93.4%) patients with stage 1, 244 (5.6%) with stage 2, and 44 
(1.0%) with stage 3 AKI. The two groups were well-balanced and showed no meaningful 
differences in 91 of 92 measured baseline characteristics (Appendix G). The ED serum 
sodium was slightly higher in the group of ED discharges with AKI [mean (SD) 137 (5) 
vs. 136 (6) mmol/L, standardized difference 22%, reference range for serum sodium: 135 
to 145 mmol/L]. 
 
The mean (SD) age of the entire matched cohort was 71 (13) years and 46.5% were 
women. The most common co-morbid conditions were hypertension (79.4%), diabetes 
(39.2%), CKD (45.0%), coronary artery disease (37.1%), and heart failure (26.7%). 
Among patients with universal drug coverage through the ODB program (79.2%), 5.2% 
resided in a long-term care facility and a median of five medications were prescribed in 
the 120 days prior to the index date. The most commonly prescribed medications were 
angiotensin-converting enzyme inhibitor or angiotensin receptor blockers (59.7%), non-
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potassium sparing diuretics (59.2%), statins (45.4%), antibiotics (45.2%), beta-adrenergic 
antagonists (39.9%), proton pump inhibitors (36.8%), and calcium channel blockers 
(34.4%). A urine ACR was measured in 23.9% of patients in the previous 365 days. Most 
patients did not have a prior ED visit (previous 30 days: 81.1%, 31 to 365 days: 60.2%) 
or hospitalization (previous 30 days: 90.0%, 31 to 365 days: 73.2%). Nearly all patients 
(98.3%) were seen by their family physician at least once in the previous 365 days. Prior 
visits to the general internist (26.4%), nephrologist (4.9%), or urologist (17.4%) were less 
common. 
 
The mean (median) pre-ED visit baseline SCr concentration among both groups was 
approximately 107 (91) µmol/L. The mean (median) ED serum potassium, sodium, and 
creatinine concentration was approximately 4.3 (4.1) mmol/L, 137 (138) mmol/L, and 
158 (139) µmol/L, respectively. Most patients were triaged to emergent or urgent acuity 
levels (CTAS 1 or 2: 27.1%, CTAS 3: 59.9%). 
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Figure 5-2: Cohort Selection for the AKI Subpopulation 
 
Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases; 
SCr, serum creatinine. 
a Patients were excluded in order as listed. 
b We selected the most recent pre-ED visit baseline SCr measurement. 
c If an individual had more than one ED visit with AKI, we selected the first ED visit. 
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Table 5-3: Baseline Characteristics of Patients in the AKI Subpopulation Pre- and Post-Match 
Variable 
Unmatched Matched 
Patient in the ED with AKIa 
Standardized 
difference 
(%) 
Patient in the ED with AKIa 
Standardized 
difference 
(%) 
Discharged 
home 
Admitted to 
hospital 
Discharged 
home 
Admitted to 
hospital 
 (N = 6346) (N= 8117) (N= 4379) (N= 4379) 
Demographics       
Age, in years       
    Mean (SD) 69 (13) 73 (13) 32 71 (13) 71 (13) 2 
    Median (IQR) 70 (58-79) 75 (64-83)  73 (62-81) 74 (62-81)  
    40 to <65 2326 (36.7) 2055 (25.3) 25 1267 (28.9) 1298 (29.6) 2 
    65 to <80 2475 (39.0) 3178 (39.2) 0 1819 (41.5) 1681 (38.4) 6 
    ≥80 1545 (24.3) 2884 (35.5) 25 1293 (29.5) 1400 (32.0) 5 
Sex, female 2948 (46.5) 3737 (46.0) 1 2037 (46.5) 2037 (46.5) 0 
Year of cohort entry       
    2003 to 2005 1593 (25.1) 1999 (24.6) 1 1114 (25.4) 1117 (25.5) 0 
    2006 to 2008 2903 (45.7) 3189 (39.3) 13 1881 (43.0) 1911 (43.6) 1 
    2009 to 2011 1850 (29.2) 2929 (36.1) 15 1384 (31.6) 1351 (30.9) 2 
Rural residence 969 (15.3) 1302 (16.0) 2 685 (15.6) 652 (14.9) 2 
Neighbourhood income  
  quintile 
      
    1 1401 (22.1) 1892 (23.3) 3 971 (22.2) 989 (22.6) 1 
    2 1353 (21.3) 1748 (21.5) 1 942 (21.5) 932 (21.3) 1 
    3 1307 (20.6) 1608 (19.8) 2 978 (22.3) 957 (21.9) 1 
    4 1046 (16.5) 1342 (16.5) 0 731 (16.7) 732 (16.7) 0 
    5 1140 (18.0) 1391 (17.1) 2 757 (17.3) 769 (17.6) 1 
Pharmacy forward sortation  
  areab 
5214 (82.2) 6513 (80.2) 5 3562 (81.3) 3573 (81.6)  1  
       
Co-morbid conditionsc        
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Abdominal aortic aneurysm  
  repair 
NR 78 (1.0) 2 38 (0.9) 38 (0.9) 0 
Atrial fibrillation or flutter NR 1133 (14.0) 11 539 (12.3) 547 (12.5) 1 
Cerebrovascular disease NR 396 (4.9) 4 221 (5.0) 208 (4.7) 1 
Chronic liver disease NR 722 (8.9) 8 327 (7.5) 325 (7.4) 0 
Chronic obstructive 
pulmonary  
  disease 
NR 907 (11.2) 18 352 (8.0) 364 (8.3) 1 
Coronary artery diseased 2160 (34.0) 3124 (38.5) 9 1614 (36.9) 1636 (37.4) 1 
Dementia NR 1204 (14.8) 15 531 (12.1) 540 (12.3) 1 
Diabetes 2405 (37.9) 3496 (43.1) 11 1728 (39.5) 1703 (38.9) 1 
Heart failure NR 2591 (31.9) 23 1168 (26.7) 1170 (26.7) 0 
Hypertension 4783 (75.4) 6454 (79.5) 10 3475 (79.4) 3475 (79.4) 0 
Major cancere 1056 (16.6) 1735 (21.4) 12 829 (18.9) 843 (19.3) 1 
Nephrolithiasis NR 191 (2.4) 2 117 (2.7) 110 (2.5) 1 
Osteoarthritis NR 631 (7.8) 2 344 (7.9) 330 (7.5) 1 
Parkinson's disease NR 82 (1.0) 5 32 (0.7) 32 (0.7) 0 
Peripheral vascular disease NR 371 (4.6) 9 154 (3.5) 156 (3.6) 0 
Rheumatoid arthritis NR 604 (7.4) 1 317 (7.2) 309 (7.1) 1 
Charlson co-morbidity indexf       
    0 4181 (65.9) 4338 (53.4) 26 2676 (61.1) 2574 (58.8) 5 
    1 NR 1017 (12.5) 5 515 (11.8) 541 (12.4) 2 
    2 NR 1110 (13.7) 11 489 (11.2) 575 (13.1) 6 
    ≥3 824 (13.0) 1652 (20.4) 20 699 (16.0) 689 (15.7) 1 
Aggregated Diagnosis  
  Groups scoreg 
      
    0-5 1757 (27.7) 1892 (23.3) 10 1124 (25.7) 1114 (25.4) 1 
    ≥6 4589 (72.3) 6225 (76.7) 10 3255 (74.3) 3265 (74.6) 1 
       
Medication utilizationh       
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ODB program eligible 4605 (72.6) 6748 (83.1) 26 3459 (79.0) 3477 (79.4) 1 
    Patients in long-term carei NR 458 (5.6) 12 172 (5.0) 188 (5.4) 2 
Medication classj       
    Alpha-1-adrenoceptor 
      antagonist or 5-alpha- 
      reductase inhibitor 
NR 439 (6.5) 0 217 (6.3) 211 (6.1) 1 
    Angiotensin-converting  
      enzyme inhibitor or 
      angiotensin receptor 
      blocker 
2750 (59.7) 4026 (59.7) 0 2065 (59.7) 2074 (59.6) 0 
    Anti-retroviral NR 12 (0.2) 0 6 (0.2) ≤5 (≤0.1) 6 
    Antibiotic 2041 (44.3) 3214 (47.6) 7 1567 (45.3) 1569 (45.1) 0 
    Anticoagulant NR 1253 (18.6) 7 594 (17.2) 609 (17.5) 1 
    Antidepressant 
      (SSRI or SNRI) 
774 (16.8) 1151 (17.1) 1 566 (16.4) 563 (16.2) 0 
    Antineoplastic  
      (chemotherapy) 
NR 150 (2.2) 2 83 (2.4) 82 (2.4) 0 
    Antiplatelet NR 1028 (15.2) 3 557 (16.1) 558 (16.0) 0 
    Antipsychotic NR 497 (7.4) 3 226 (6.5) 228 (6.6) 0 
    Beta-adrenergic antagonist 1781 (38.7) 2712 (40.2) 3 1385 (40.0) 1381 (39.7) 1 
    Calcium channel blocker NR 2357 (34.9) 2 1193 (34.5) 1196 (34.4) 0 
    Corticosteroid 1188 (25.8) 1904 (28.2) 5 935 (27.0) 943 (27.1) 0 
    Immunosuppressive  
      medication 
NR 291 (4.3) 2 144 (4.2) 127 (3.7) 3 
    Lithium NR 45 (0.7) 0 23 (0.7) 21 (0.6) 1 
    Non-potassium sparing  
      diuretic 
2609 (56.7) 4213 (62.4) 12 2034 (58.8) 2071 (59.6) 2 
    Non-steroidal anti- 
      inflammatory drugk 
892 (19.4) 1245 (18.4) 2 660 (19.1) 657 (18.9) 0 
    Oral hypoglycemic agent 
      or insulin 
NR 2069 (30.7) 0 1039 (30.0) 1016 (29.2) 2 
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    Potassium-sparing diuretic NR 1013 (15.0) 9 445 (12.9) 481 (13.8) 3 
    Proton pump inhibitor 1651 (35.9) 2563 (38.0) 4 1260 (36.4) 1289 (37.1) 1 
    Statin 2174 (47.2) 2932 (43.4) 8 1584 (45.8) 1563 (45.0) 2 
    Xanthine oxidase inhibitor  
      or uricosuric agent 
NR 576 (8.5) 7 245 (7.1) 262 (7.5) 2 
Unique drug names       
    Mean (SD) 6 (6) 7 (5) 27 6 (6) 6 (6) 1 
    Median (IQR) 5 (0-10) 6 (0-10)  6 (0-10) 6 (0-10)  
Unique drug identification  
  numbers 
      
    Mean (SD) 6 (6) 8 (7) 27 7 (6) 7 (6) 2 
    Median (IQR) 5 (0-10) 7 (0-11)  6 (0-11) 6 (0-11)  
       
Pre-ED visit baseline kidney 
functionl 
      
Baseline SCr, in µmol/L 
    Mean (SD) 101 (55) 115 (69) 23 106 (57) 107 (59) 2 
    Median (IQR) 87 (71-112) 96 (76-130)  90 (74-118) 91 (73-120)  
Days baseline SCr measured 
  pre-ED visit 
      
    Mean (SD) 133 (102) 121 (99) 12 127 (101) 128 (101) 1 
    Median (IQR) 106 (44-207) 90 (36-188)  98 (41-197) 100 (40-203)  
Baseline SCr ≤50 µmol/L NR 277 (3.4) 4 164 (3.7) 165 (3.8) 1 
Baseline eGFR       
    ≥60 ml/min/1.73m2 3919 (61.8) 3907 (48.1) 28 2435 (55.6) 2386 (54.5) 2 
    45 to <60 ml/min/1.73m2 NR 1610 (19.8) 8 815 (18.6) 834 (19.0) 1 
    30 to <45 ml/min/1.73m2 NR 1470 (18.1) 13 695 (15.9) 685 (15.6) 1 
    <30 ml/min/1.73m2 NR 1130 (13.9) 19 434 (9.9) 474 (10.8) 3 
CKD risk categorym       
    Low risk NR 558 (6.9) 16 422 (9.6) 352 (8.0) 6 
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    Moderate risk NR 382 (4.7) 1 201 (4.6) 208 (4.7) 1 
    High risk NR 394 (4.9) 5 248 (5.7) 236 (5.4) 1 
    Very high risk NR 1358 (16.7) 18 551 (12.6) 586 (13.4) 2 
Urine ACR measured 1689 (26.6) 1794 (22.1) 11 1078 (24.6) 1019 (23.3) 3 
    <3 mg/mmol NR 1014 (12.5) 10 633 (14.5) 567 (12.9) 4 
    3 to <30 mg/mmol NR 363 (4.5) 1 186 (4.2) 208 (4.7) 2 
    ≥30 mg/mmol NR 417 (5.1) 5 259 (5.9) 244 (5.6) 1 
       
ED visit laboratory 
characteristics 
      
Serum potassium, in mmol/L       
    Mean (SD) 4.2 (0.6) 4.4 (0.9) 31 4.2 (0.6) 4.3 (0.8) 7 
    Median (IQR) 4.1 (3.8-4.5) 4.3 (3.8-4.9)  4.1 (3.8-4.5) 4.1 (3.7-4.7)  
Serum sodium, in mmol/L       
    Mean (SD) 137 (5) 136 (7) 25 137 (5) 136 (6) 22 
    Median (IQR) 138 (135-140) 136 (133-139)  138 (135-140) 137 (134-139)  
SCr, in µmol/L       
    Mean (SD) 147 (70) 208 (158) 50 156 (74) 158 (73) 3 
    Median (IQR) 129 (109-162) 162 (124-230)  136 (113-174) 139 (114-178)  
AKI severity       
    Stage 1 6012 (94.7) 6407 (78.9) 48 4091 (93.4) 4091 (93.4) 0 
    Stage 2 290 (4.6) 1007 (12.4) 28 244 (5.6) 244 (5.6) 0 
    Stage 3 44 (0.7) 703 (8.7) 38 44 (1.0) 44 (1.0) 0 
       
Previous health care 
utilizationn 
      
ED visits in the previous       
    30 days 1114 (17.6) 1638 (20.2) 7 818 (18.7) 840 (19.2) 1 
    31 to 365 days 2510 (39.5) 3252 (40.1) 1 1744 (39.8) 1743 (39.8) 0 
Hospitalizations in the        
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  previous 
    30 days 481 (7.6) 1130 (13.9) 21 419 (9.6) 454 (10.4) 3 
    31 to 365 days 1452 (22.9) 2387 (29.4) 15 1102 (25.2) 1245 (28.4) 7 
Outpatient physician visits       
    Family physician 6251 (98.5) 7965 (98.1) 3 4319 (98.6) 4294 (98.1) 4 
        0 to 4 visits 1069 (16.8) 1239 (15.3) 4 646 (14.8) 732 (16.7) 5 
        5 to 10 visits 2287 (36.0) 2571 (31.7) 9 1521 (34.7) 1429 (32.6) 4 
        ≥11 visits 2990 (47.1) 4307 (53.1) 12 2212 (50.5) 2218 (50.7) 0 
    General internist (≥1 visit) 1470 (23.2) 2486 (30.6) 17 1143 (26.1) 1171 (26.7) 1 
    Nephrologist (≥1 visit) NR 496 (6.1) 7 226 (5.2) 204 (4.7) 2 
    Urologist (≥1 visit) 1132 (17.8) 1390 (17.1) 2 791 (18.1) 729 (16.6) 4 
Diagnostic imaging and  
  procedures 
      
    Abdominal ultrasoundo 1530 (24.1) 2210 (27.2) 7 883 (20.2) 886 (20.2) 0 
    Cardiac stress test NR 1056 (13.0) 6 619 (14.1) 627 (14.3) 0 
    Coronary angiogram or 
      revascularization 
NR 157 (1.9) 2 91 (2.1) 102 (2.3) 2 
    CT scan with contrast NR 407 (5.0) 11 157 (3.6) 158 (3.6) 0 
    Echocardiogram NR 1820 (22.4) 11 1080 (24.7) 1083 (24.7) 0 
    Intervention for kidney  
      stonesp 
NR 96 (1.2) 0 50 (1.1) 50 (1.1) 1 
       
ED and hospital 
characteristics 
      
Institutionq       
1 1754 (27.6) 2565 (31.6) 9 1336 (30.5) 1317 (30.1) 1 
2 1482 (23.4) 2051 (25.3) 4 1060 (24.2) 1089 (24.9) 2 
3 NR 806 (9.9) 1 464 (10.6) 472 (10.8) 1 
4 NR 74 (0.9) 33 61 (1.4) 62 (1.4) 0 
5 NR 150 (1.8) 4 94 (2.1) 107 (2.4) 2 
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6 NR 70 (0.9) 2 36 (0.8) 31 (0.7) 1 
7 NR 833 (10.3) 2 466 (10.6) 447 (10.2) 1 
8 NR 332 (4.1) 1 180 (4.1) 186 (4.2) 1 
9 NR 369 (4.5) 5 246 (5.6) 242 (5.5) 0 
10 NR 657 (8.1) 8 308 (7.0) 295 (6.7) 1 
11 NR 139 (1.7) 5 88 (2.0) 90 (2.1) 0 
12 NR 39 (0.5) 1 22 (0.5) 23 (0.5) 0 
13 NR 32 (0.4) 1 18 (0.4) 18 (0.4) 0 
       
ED and hospital activity       
    Standardized number of  
      ED registrations in the  
      last 12hr 
      
        Mean (SD) 1.1 (0.3) 1.1 (0.3) 14 1.1 (0.3) 1.1 (0.3) 0 
        Median (IQR) 1.1 (0.9-1.3) 1.1 (0.9-1.3)  1.9 (0.9-1.3) 1.9 (0.9-1.3)  
    Standardized number of  
      hospital admissions 
      in the last 24hs 
      
        Mean (SD) 1.1 (0.3) 1.1 (0.3) 3 1.1 (0.3) 1.1 (0.3) 0 
        Median (IQR) 1.1 (0.8-1.3) 1.1 (0.8-1.3)  1.1 (0.8-1.3) 1.1 (0.8-1.3)  
    Standardized number of  
      hospital inpatient 
      discharges in the last 24ht 
      
        Mean (SD) 1.1 (0.4) 1.1 (0.4) 3 1.1 (0.3) 1.1 (0.4) 3 
        Median (IQR) 1.1 (0.8-1.2) 1.1 (0.8-1.3)  1.1 (0.8-1.3) 1.1 (0.8-1.3)  
    Standardized number of  
      ED registrations resulting  
      in hospitalization, in %u 
47.0 51.0 8 49.5 49.3 0 
ED seasonal and time  
  characteristics 
      
    Time of day       
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        0700 to <1700 3320 (52.3) 4538 (71.5) 40 2298 (52.5) 2381 (54.4) 4 
        1700 to <2400 2226 (35.1) 2495 (39.3) 9 1497 (34.2) 1423 (32.5) 4 
        0000 to <0700 800 (12.6) 1084 (17.1) 13 584 (13.3) 575 (13.1) 1 
    Seasonv       
        Fall 1502 (23.7) 2141 (26.4) 6 1067 (24.4) 1105 (25.2) 2 
        Winter 1446 (22.8) 1925 (23.7) 2 1033 (23.6) 1013 (23.1) 1 
        Spring 1635 (25.8) 1959 (24.1) 4 1108 (25.3) 1086 (24.8) 1 
        Summer 1763 (27.8) 2092 (25.8) 5 1171 (26.7) 1175 (26.8) 0 
ED physician training       
    Emergency medicine 4642 (73.1) 5781 (71.2) 4 3140 (71.7) 3152 (72.0) 1 
    Family medicine 1338 (21.1) 1602 (19.7) 3 945 (21.6) 936 (21.4) 1 
    Other NR 734 (9.0) 13 294 (6.7) 291 (6.6) 0 
       
ED patient acuity and wait 
times 
      
CTASw       
    1 or 2 1321 (20.8) 3142 (38.7) 40 1192 (27.2) 1185 (27.1) 0 
    3 3797 (59.8) 4257 (52.4) 15 2620 (59.8) 2626 (60.0) 0 
    4 or 5 1228 (19.4) 718 (8.8) 31 567 (12.9) 568 (13.0) 0 
Time (hours) waiting for  
  physician assessment, mean  
  (SD) 
      
    CTAS 1 or 2 0.6 (0.8) 0.5 (0.8) 16 0.6 (0.8) 0.5 (0.6) 7 
    CTAS 3 1.3 (1.3) 1.2 (1.2) 12 1.3 (1.1) 1.2 (1.2) 3 
    CTAS 4 or 5 1.6 (1.4) 1.7 (1.7) 2 1.4 (1.3) 1.6 (1.6) 9 
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED, 
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ODB, Ontario Drug Benefit; NR, not reported; SD, standard deviation; SCr, serum 
creatinine; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. 
To convert SCr from SI units (µmol/L) to traditional units (mg/dL), divide by 88.42. 
a Data reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in 
the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients. 
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b Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of 
individuals who live in the same region as the pharmacy that provided them with prescription medications.  
c Look-back window for co-morbidities was five years unless otherwise noted. 
d Does not include angina. 
e Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus. 
f Look-back window for the Charlson co-morbidity index was two years.63,64 
g The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization 
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care 
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG 
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization. 
h Look-back window for medication utilization was 120 days. 
i Patients in long-term care were identified from the ODB database. 
j Percentages reported are based on the number of ODB program eligible patients (age 65 years and older). 
k Does not includes acetylsalicylic acid. 
l Pre-ED look-back window was 7 to 365 days. 
m CKD risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes consensus guidelines. In addition to using urine ACR measurements, urine dipstick 
and protein values were converted to an estimate urine ACR.67 
n Look-back window for health care utilization was 365 days unless otherwise noted. 
o Not specific for the assessment of the kidneys. 
p Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal. 
q For privacy considerations, individual hospital institutions were not identified. 
r Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days. 
s Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days. 
t Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days. 
u Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours. 
v Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20. 
w Patients with a CTAS of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a CTAS of 3 or 4 need to be seen 
within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes 80% of the time. 
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5.2.1.3 Outcomes 
The primary and secondary outcome for the AKI subpopulation is shown in Table 5-4. In 
the 30-day follow-up period across the entire cohort, 652 (7.4%) patients died and 52 
(0.6%) received hospital-based acute dialysis. 
 
Compared to patients admitted to hospital from the ED with AKI, fewer patients 
discharged home from the ED with AKI died within 30 days of the index date [130 
(3.0%) vs. 522 (11.9%), RR: 0.25, 95% CI: 0.21-0.30, P<0.001]. Fewer patients 
discharged home from the ED with AKI received hospital-based acute dialysis within 30 
days of the index date, although the difference did not reach statistical significance [19 
(0.43%) vs. 33 (0.75%), RR: 0.57, 95% CI: 0.33 to 1.01, P=0.06]. 
 
5.2.1.4 Subgroup Analysis 
A subgroup analysis for all-cause mortality by AKI stage is shown in Table 5-5. The 
relative association between an ED discharge and the risk of all-cause mortality was 
attenuated with more severe forms of AKI [stage 1 RR (95% CI): 0.23 (0.18-0.29), stage 
2: 0.40 (0.22-0.69), and stage 3: 1.00 (0.38-2.64); P value for interaction <0.001)]. 
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Table 5-4: Thirty-Day Risk of All-Cause Mortality and Need for Hospital-Based Acute 
Dialysis in a Matched Cohort of Patients in the AKI Subpopulation 
 ED patient events, n (%)   
Outcome 
Discharged 
home with 
AKI 
(N = 4379) 
Admitted to 
hospital with 
AKI 
(N = 4379) 
Relative riska 
(95% CI) P value 
All-cause mortality 130 (3.0) 522 (11.9) 0.25 (0.21-0.30) <0.001 
 
Receipt of hospital- 
  based acute dialysis 
19 (0.4) 33 (0.8) 0.57 (0.33-1.01) 0.06 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department. 
a Patients admitted to hospital from the ED with AKI served as the referent group. 
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Table 5-5: The Association Between Emergency Department Disposition and 30-Day 
All-Cause Mortality in the AKI Subpopulation Examined in a Subgroup Defined by 
Acute Kidney Injury Stage 
 ED patient events, n/N (%)a   
AKI stage Discharged home with AKI 
Admitted to 
hospital with AKI 
Relative riskb 
(95% CI) 
Interaction 
P value 
    1 108/4091 (2.6) 477/4091 (11.7) 0.23 (0.18-0.28) 
<0.001     2 15/244 (6.1) 38/244 (15.6) 0.40 (0.22-0.69) 
    3 7/44 (15.9) 7/44 (15.9) 1.00 (0.38-2.64) 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department. 
a n = number of events, N = number at risk. 
b Patients admitted to hospital from the ED with AKI served as the referent group.
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5.2.2 Discharged Subpopulation 
5.2.2.1 Unmatched Cohort 
Cohort selection for the AKI subpopulation is presented in Figure 5-3. Baseline 
characteristics before and after matching are presented in Table 5-6. 
 
Before matching, there were 49,768 patients who visited an ED and were discharged 
home. Among these patients, 6346 had AKI and 43,422 did not have AKI. ED patients 
discharged home with AKI as compared to those with no AKI were older (mean age 69 
vs. 63 years) and more likely to have coronary artery disease (34.0 vs. 20.0%), CKD 
(38.2 vs. 17.3%), diabetes (37.9 vs. 24.6%), hypertension (75.4 vs. 59.2%), a Charlson 
co-morbidity index of ≥3: 13.0 vs. 4.5%, an ADG score of ≥6: 72.3 vs. 59.5%, universal 
drug coverage (72.6 vs. 52.6%), be prescribed a greater number of medications (median 6 
vs. 3) in the previous 120 days such as angiotensin-converting enzyme inhibitors or 
angiotensin II receptor blockers, antibiotics, beta-adrenergic antagonists, non-potassium 
sparing medications, oral hypoglycemic agents or insulin, proton pump inhibitors, and 
statins, have a higher pre-ED visit baseline SCr concentration [mean (median) 101 (87) 
vs. 81 (76) µmol/L], have a previous abdominal ultrasound (24.1 vs. 19.1%), a prior ED 
visit (previous 30 days: 17.6 vs. 8.6%; 31 to 365 days: 39.5 vs. 32.0%) or hospitalization 
(previous 31 to 365 days: 22.9 vs. 13.7%), be seen by a family physician ≥11 times in the 
past year (47.1 vs. 31.1%), and be seen at least once by a urologist (17.8 vs. 11.7%). 
These patients were more likely to visit the ED in the evening (35.1 vs. 27.8%), have a 
higher ED serum potassium concentration [mean (median) 4.2 (4.1) vs. 4.0 (3.9) 
mmol/L], and have a lower ED serum sodium concentration [mean (median) 137 (138) 
vs. 138 (139) mmol/L]. 
 
ED patients discharged home with AKI as compared to those with no AKI were less 
likely to be female (46.5 vs. 56.5%), have an eGFR ≥60 mL/min/1.73m2 (61.8 vs. 
82.7%), and visit an ED during daytime hours (52.3 vs. 57.6%). 
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There was no difference in rural residence, income, abdominal aortic aneurysm repair, 
chronic liver disease, major cancer, nephrolithiasis, osteoarthritis, Parkinson’s disease, 
and rheumatoid arthritis, use of alpha-one-adrenoceptor antagonists or five-alpha-
reductase inhibitors, anti-retrovirals, antidepressants, antineoplastics, antipsychotics, 
corticosteroids, immunosuppression, lithium, or non-steroidal anti-inflammatory drugs, 
number of days the pre-ED visit baseline SCr was measured prior to the index date, 
proportion of patients with pre-ED visit baseline SCr ≤50 µmol/L, proportion of patients 
with a pre-ED visit urine ACR measurement, hospitalization in the previous 30 days, at 
least one family physician visit, at least one general internist visit, cardiac stress test, 
coronary angiogram or revascularization, intervention for kidney stones, season of the 
year, CTAS, time waiting for a physician assessment, any ED physician specialty, and 
90th percentile for ED length of stay. 
 
5.2.2.2 Matched Cohort 
A total of 6188 patients discharged home from the ED with AKI were successfully 
matched to 6188 patients discharged home from the ED with no AKI (Table 5-6). The 
matched cohort comprised of 3904 (63.1%) patients with an eGFR ≥60, 1054 (17.0%) 
with an eGFR 45 to <60, 803 (13.0%) with an eGFR 30 to <45, and 427 (6.9%) with an 
eGFR <30 mL/min/1.73m2. The two groups were well-balanced and showed no 
meaningful differences in 89 of 91 measured baseline characteristics (Appendix G). The 
group discharged home from the ED with AKI had a higher mean (SD) ED serum 
potassium concentration [4.2 (0.6) vs. 4.0 (0.5) mmol/L, standardized difference 21%, 
reference range: 3.5 to 5.0 mmol/L] and was more likely to visit an ED in the previous 30 
days (17.1 vs. 13.5%, standardized difference 10.1%). 
 
The mean (SD) age of the entire matched cohort was 69 (14) years and 47.2% were 
women. The most common co-morbid conditions were hypertension (75.1%), diabetes 
(37.2%), CKD (36.9%), coronary artery disease (33.2%), and heart failure (20.2%). In 
patients with universal drug coverage through the ODB program (72.6%), 3.6% resided 
in a long-term care facility and a median of five medications were prescribed in the 120 
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days prior to the index date. The most commonly prescribed medications were 
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (59.2%), non-
potassium sparing diuretics (55.4%), statins (46.3%), antibiotics (43.7%), beta-adrenergic 
antagonists (38.0%), proton pump inhibitors (34.9%), and calcium channel blockers 
(32.9%). A urine ACR was measured in 26.2% of patients in the previous 365 days. Most 
patients did not have a prior ED visit (previous 30 days: 84.7%, 31 to 365 days: 61.4%) 
or hospitalization (previous 30 days: 92.8%, 31 to 365 days: 77.7%). Nearly all patients 
(98.5%) were seen by their family physician at least once in the previous 365 days. Prior 
visits to the general internist (22.8%), nephrologist (3.8%), and urologist (17.4%) were 
less common. 
 
The mean (median) pre-ED visit baseline SCr concentration was approximately 98 (87) 
µmol/L. The mean (median) ED serum potassium and sodium concentration was 
approximately 4.2 (4.0) mmol/L and 138 (139) mmol/L, respectively. Most patients were 
triaged to emergent or urgent acuity levels (CTAS 1 or 2: 20.9%, CTAS 3: 58.1%). The 
90th percentile for ED length of stay ranged between 8 and 9 hours. 
 
5.2.2.3 Outcomes 
The primary and secondary outcome for the discharged subpopulation is shown in Table 
5-7. In the 30-day follow-up period across the entire cohort, 223 (3.6%) patients died and 
26 (0.4%) received hospital-based acute dialysis. 
 
Compared to patients discharged from the ED with no AKI, more patients discharged 
home from the ED with AKI died [136 (2.2%) vs. 87 (1.4%), RR: 1.56, 95% CI: 1.20 to 
2.04, P=0.001] and received hospital-based acute dialysis within 30 days of the index 
date [19 (0.43%) vs. 7 (0.11%), RR: 2.71, 95% CI: 1.22 to 6.02, P=0.01]. 
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5.2.2.4 Subgroup Analysis 
A subgroup analysis for all-cause mortality by CKD stage is shown in Table 5-8. The 
association between AKI and the risk of all-cause mortality was not modified by CKD 
stage (P value for interaction <0.57).
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Figure 5-3: Cohort Selection for the Discharged Subpopulation  
 
Abbreviations: AKI, acute kidney injury; ED, emergency department; ICD, International Classification of Diseases; 
SCr, serum creatinine. 
a Patients were excluded in order as listed. 
b We selected the most recent pre-ED visit baseline SCr measurement. 
c If an individual had more than one ED visit with AKI, we selected the first ED visit. 
d If an individual had more than one ED visit with no AKI, we selected the first ED visit. However, preference was 
given to the group discharged home from the ED with AKI if patients were also eligible for this referent group.
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Table 5-6: Baseline Characteristics of Patients in the Discharged Subpopulation Pre- and Post-Match 
Variable 
Unmatched Matched 
Discharged homea Standardized 
difference 
Discharged homea Standardized 
difference AKI No AKI AKI No AKI 
(N = 6346) (N = 43422) (%) (N = 6188) (N = 6188) (%) 
Demographics       
Age, in years       
    Mean (SD) 69 (13) 63 (14) 42 68 (13) 69 (14) 2 
    Median (IQR) 70 (58-79) 62 (51-74)  70 (58-79) 71 (58-80)  
    40 to <65 2326 (36.7) 24036 (55.4) 38 2309 (37.3) 2190 (35.4) 4 
    65 to <80 2475 (39.0) 13061 (30.1) 19 2401 (38.8) 2429 (39.3) 1 
    ≥80 1545 (24.3) 6325 (14.6) 25 1478 (23.9) 1569 (25.4) 3 
Sex, female 2948 (46.5) 24532 (56.5) 20 2900 (46.9) 2940 (47.5) 1 
Year of cohort entry       
    2003 to 2005 1593 (25.1) 8611 (19.8) 13 1559 (25.2) 1558 (25.2) 0 
    2006 to 2008 2903 (45.7) 17056 (39.3) 13 2811 (45.4) 2839 (45.9) 1 
    2009 to 2011 1850 (29.2) 17755 (40.9) 25 1818 (29.4) 1791 (28.9) 1 
Rural residence 969 (15.3) 6299 (14.5) 2 940 (15.2) 957 (15.5) 1 
Neighbourhood income  
  quintile       
    1 1401 (22.1) 8814 (20.3) 4 1372 (22.2) 1416 (22.9) 2 
    2 1353 (21.3) 9012 (20.8) 1 1306 (21.1) 1323 (21.4) 1 
    3 1307 (20.6) 8757 (20.2) 1 1372 (22.2) 1330 (21.5) 2 
    4 1046 (16.5) 7896 (18.2) 4 1023 (16.5) 999 (16.1) 1 
    5 1140 (18.0) 8520 (19.6) 4 1115 (18.0) 1120 (18.1) 0 
Pharmacy forward sortation  
  areab 5214 (82.2) 34871 (80.3) 5 5089 (82.2) 5059 (81.8) 1 
       
Co-morbid conditionsc       
Abdominal aortic aneurysm  NR 162 (0.4) 5 47 (0.8) 55 (0.9) 1 
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  repair 
Atrial fibrillation or flutter NR 1759 (4.1) 24 606 (9.8) 581 (9.4) 1 
Cerebrovascular disease NR 706 (1.6) 15 234 (3.8) 230 (3.7) 0 
Chronic liver disease NR 2203 (5.1) 7 412 (6.7) 392 (6.3) 1 
Chronic obstructive pulmonary  
  disease NR 1140 (2.6) 17 359 (5.8) 337 (5.4) 2 
Coronary artery diseased 2160 (34.0) 8678 (20.0) 32 2062 (33.3) 2049 (33.1) 0 
Dementia NR 2428 (5.6) 16 607 (9.8) 614 (9.9) 0 
Diabetes 2405 (37.9) 10678 (24.6) 29 2294 (37.1) 2308 (37.3) 0 
Heart failure NR 3460 (8.0) 39 1280 (20.7) 1226 (19.8) 2 
Hypertension 4783 (75.4) 25725 (59.2) 35 4630 (74.8) 4668 (75.4) 1 
Major cancere 1056 (16.6) 5918 (13.6) 8 1026 (16.6) 1016 (16.4) 0 
Nephrolithiasis NR 666 (1.5) 8 169 (2.7) 170 (2.7) 0 
Osteoarthritis NR 2580 (5.9) 5 444 (7.2) 434 (7.0) 1 
Parkinson's disease NR 114 (0.3) 4 32 (0.5) 38 (0.6) 1 
Peripheral vascular disease NR 1759 (4.1) 13 174 (2.8) 163 (2.6) 1 
Rheumatoid arthritis NR 2595 (6.0) 5 445 (7.2) 437 (7.1) 1 
Charlson co-morbidity indexf       
    0 4181 (65.9) 35911 (82.7) 39 4139 (66.9) 4246 (68.6) 4 
    1 NR 2900 (6.7) 15 683 (11.0) 640 (10.3) 2 
    2 NR 2657 (6.1) 15 618 (10.0) 639 (10.3) 1 
    ≥3 824 (13.0) 1954 (4.5) 30 748 (12.1) 663 (10.7) 4 
Aggregated Diagnosis Groups  
  scoreg       
    0-5 1757 (27.7) 17586 (40.5) 27 1738 (28.1) 1777 (28.7) 1 
    ≥6 4589 (72.3) 25836 (59.5) 27 4450 (71.9) 4411 (71.3) 1 
       
Medication utilizationh       
ODB eligible 4605 (72.6) 22849 (52.6) 42 3459 (79.0) 3477 (79.4) 3 
     Patients in long-term  NR 441 (1.9) 12 172 (3.9) 188 (4.3) 2 
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       carei 
Medication classj       
    Alpha-1-adrenoceptor  
      antagonist or 5-alpha- 
      reductase inhibitor 
NR 1078 (4.7) 7 277 (6.2) 255 (5.6) 3 
    Angiotensin-converting  
      enzyme inhibitor or  
      angiotensin receptor  
      blocker 
2750 (59.7) 10530 (46.1) 28 2644 (59.4) 2680 (59.1) 1 
    Anti-retroviral NR 40 (0.2) 0 7 (0.2) 8 (0.2) 0 
    Antibiotic 2041 (44.3) 8297 (36.3) 16 1954 (43.9) 1972 (43.5) 1 
    Anticoagulant NR 2287 (10.0) 17 673 (15.1) 646 (14.2) 2 
    Antidepressant 
      (SSRI or SNRI) 
774 (16.8) 3534 (15.5) 4 738 (16.6) 767 (16.9) 1 
    Antineoplastic  
      (chemotherapy) 
NR 463 (2.0) 3 110 (2.5) 121 (2.7) 1 
    Antiplatelet NR 2442 (10.7) 16 705 (15.8) 712 (15.7) 0 
    Antipsychotic NR 1335 (5.8) 3 286 (6.4) 298 (6.6) 1 
    Beta-adrenergic antagonist 1781 (38.7) 6467 (28.3) 22 1697 (38.1) 1716 (37.8) 1 
    Calcium channel blocker NR 5647 (24.7) 21 1488 (33.4) 1468 (32.4) 2 
    Corticosteroid 1188 (25.8) 5280 (23.1) 6 1155 (25.9) 1172 (25.8) 0 
    Immunosuppressive  
      medication 
NR 784 (3.4) 3 175 (3.9) 184 (4.1) 1 
    Lithium NR 171 (0.7) 1 30 (0.7) 30 (0.7) 0 
    Non-potassium sparing  
      diuretic 
2609 (56.7) 8421 (36.9) 40 2476 (55.6) 2504 (55.2) 1 
    Non-steroidal anti- 
      inflammatory drugk 
892 (19.4) 4347 (19.0) 1 871 (19.6) 894 (19.7) 0 
    Oral hypoglycemic agent or  
      insulin 
NR 4221 (18.5) 28 1320 (29.6) 1328 (29.3) 1 
    Potassium-sparing NR 1431 (6.3) 20 512 (11.5) 505 (11.1) 1 
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      diuretic 
    Proton pump inhibitor 1651 (35.9) 6878 (30.1) 12 1588 (35.7) 1548 (34.1) 3 
    Statin 2174 (47.2) 9087 (39.8) 15 2085 (46.8) 2075 (45.8) 2 
    Xanthine oxidase  
      inhibitor or uricosuric  
      agent 
NR 703 (3.1) 17 273 (6.1) 269 (5.9) 1 
Unique drug names       
    Mean (SD) 6 (6) 3 (4) 54 5 (5) 5 (5) 0 
    Median (IQR) 5 (0-10) 3 (0-9)  5 (0-9) 5 (0-9)  
Unique drug identification  
  numbers       
    Mean (SD) 6 (6) 3 (5) 54 6 (6) 6 (6) 0 
    Median (IQR) 5 (0-10) 3 (0-10)  5 (0-10) 5 (0-10)  
       
Pre-ED visit baseline kidney 
functionl       
Baseline SCr, in µmol/L 
    Mean (SD) 101 (55) 81 (28) 45 98 (50) 98 (49) 1 
    Median (IQR) 87 (71-112) 76 (65-90)  86 (71-109) 87 (71-110)  
Days baseline SCr  
  measured pre-ED visit       
    Mean (SD) 133 (102) 137 (103) 4 133 (102) 134 (103) 0 
    Median (IQR) 106 (44-207) 114 (46-215)  107 (45-209) 106 (43-210)  
Baseline SCr ≤50 µmol/L NR 1309 (3.0) 6 263 (4.3) 264 (4.3) 0 
Baseline eGFR       
    ≥60 ml/min/1.73m2 3919 (61.8) 35924 (82.7) 48 3904 (63.1) 3904 (63.1) 0 
    45 to <60 ml/min/1.73m2 NR 4836 (11.1) 16 1054 (17.0) 1054 (17.0) 0 
    30 to <45 ml/min/1.73m2 NR 2022 (4.7) 31 803 (13.0) 803 (13.0) 0 
    <30 ml/min/1.73m2 NR 640 (1.5) 31 427 (6.9) 427 (6.9) 0 
CKD risk categorym       
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    Low risk NR 6393 (14.7) 10 721 (11.7) 679 (11.0) 2 
    Moderate risk NR 1436 (3.3) 8 304 (4.9) 296 (4.8) 1 
    High risk NR 1910 (4.4) 7 377 (6.1) 391 (6.3) 1 
    Very high risk NR 988 (2.3) 34 578 (9.3) 570 (9.2) 0 
Urine ACR measured 1689 (26.6) 10210 (23.5) 7 1648 (26.6) 1591 (25.7) 2 
    <3mg/mmol NR 7404 (17.1) 3 999 (16.1) 964 (15.6) 2 
    3 to <30 mg/mmol NR 978 (2.3) 12 267 (4.3) 228 (3.7) 3 
    ≥30 mg/mmol NR 1828 (4.2) 9 382 (6.2) 399 (6.4) 1 
       
ED visit laboratory 
characteristics       
Serum potassium, in mmol/L       
    Mean (SD) 4.2 (0.6) 4.0 (0.5) 33 4.2 (0.6) 4.0 (0.5) 21 
    Median (IQR) 4.1 (3.8-4.5) 3.9 (3.7-4.2)  4.0 (3.8-4.5) 4.0 (3.7-4.3)  
Serum sodium, in mmol/L       
    Mean (SD) 137 (5) 138 (4) 20 138 (5) 138 (4) 10n 
    Median (IQR) 138 (135-140) 139 (137-141)  138 (136-140) 139 (136-140)  
       
Previous health care 
utilizationo       
ED visits in the previous       
    30 days 1114 (17.6) 3745 (8.6) 27 1061 (17.1) 836 (13.5) 10p 
    31 to 365 days 2510 (39.5) 13880 (32.0) 16 2438 (39.4) 2335 (37.7) 3 
Hospitalizations in the  
  previous       
    30 days 481 (7.6) 2421 (5.6) 8 460 (7.4) 429 (6.9) 2 
    31 to 365 days 1452 (22.9) 5928 (13.7) 24 1375 (22.2) 1390 (22.5) 1 
Outpatient physician visits       
    Family physician 6251 (98.5) 42483 (97.8) 5 6095 (98.5) 6098 (98.5) 0 
        0 to 4 visits 1069 (16.8) 11584 (26.7) 24 1058 (17.1) 1072 (17.3) 1 
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        5 to 10 visits 2287 (36.1) 18323 (42.2) 13 2258 (36.5) 2314 (37.4) 2 
        ≥11 visits 2990 (47.1) 13515 (31.1) 33 2872 (46.4) 2802 (45.3) 2 
    General internist (≥1 visit) 1470 (23.2) 6619 (15.2) 4 1407 (22.7) 1420 (22.9) 1 
    Nephrologist (≥1 visit) NR 561 (1.3) 29 260 (4.2) 209 (3.4) 4 
    Urologist (≥1 visit) 1132 (17.8) 5085 (11.7) 40 1103 (17.8) 1046 (16.9) 2 
Diagnostic imaging or  
  procedures 
      
    Abdominal ultrasoundq 1530 (24.1) 8291 (19.1) 12 1480 (23.9) 1465 (23.7) 1 
    Cardiac stress test NR 5584 (12.9) 7 948 (15.3) 929 (15.0) 1 
    Coronary angiogram or  
      revascularization 
NR 702 (1.6) 5 144 (2.3) 135 (2.2) 1 
    CT with contrast NR 636 (1.5) 10 172 (2.8) 175 (2.8) 0 
    Echocardiogram NR 5204 (12.0) 17 1077 (17.4) 1004 (16.2) 3 
    Intervention for kidney  
      stonesr 
NR 270 (0.6) 6 77 (1.2) 79 (1.3) 0 
       
ED and hospital 
characteristics       
Institutions       
1 1754 (27.6) 13190 (30.4) 6 1724 (27.9) 1679 (27.1) 2 
2 1482 (23.4) 11867 (27.3) 9 1448 (23.4) 1445 (23.4) 0 
3 NR 3128 (7.2) 11 626 (10.1) 629 (10.2) 0 
4 NR 2967 (6.8) 2 456 (7.4) 469 (7.6) 1 
5 NR 1108 (2.6) 0 156 (2.5) 154 (2.5) 0 
6 NR 262 (0.6) 1 42 (0.7) 41 (0.7) 0 
7 NR 3143 (7.2) 8 587 (9.5) 579 (9.4) 0 
8 NR 1583 (3.6) 1 242 (3.9) 250 (4.0) 1 
9 NR 1651 (3.8) 8 337 (5.4) 327 (5.3) 1 
10 NR 2883 (6.6) 3 369 (6.0) 382 (6.2) 1 
11 NR 1174 (2.7) 2 145 (2.3) 158 (2.6) 1 
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12 NR 271 (0.6) 1 34 (0.5) 48 (0.8) 4 
13 NR 195 (0.4) 1 22 (0.4) 27 (0.4) 0 
ED and hospital activity       
Standardized number of 
  ED registrations 
  in the last 12ht 
      
        Mean (SD) 1.1 (0.3) 1.1 (0.3) 20 1.1 (0.3) 1.1 (0.3) 0 
        Median (IQR) 1.1 (0.9-1.3) 1.0 (0.8-1.3)  1.1 (0.9-1.3) 1.1 (0.9-1.3)  
    Standardized number of  
      hospital admissions 
      in the last 24hu 
      
        Mean (SD) 1.1 (0.3) 1.1 (0.3) 3 1.1 (0.3) 1.1 (0.3) 3 
        Median (IQR) 1.1 (0.8-1.3) 1.1 (0.8-1.2)  1.1 (0.8-1.3) 1.1 (0.8-1.3)  
    Standardized number of  
      hospital inpatient  
      discharges in the last 24hv 
      
        Mean (SD) 1.1 (0.4) 1.1 (0.3) 3 1.1 (0.3) 1.1 (0.4) 0 
        Median (IQR) 1.1 (0.8-1.2) 1.1 (0.8-1.3)  1.1 (0.8-1.2) 1.1 (0.8-1.2)  
    Standardized number of ED  
      registrations resulting in  
      hospitalization, in %w 
47.0 49.0 4 47.3 47.1 0 
ED seasonal and time  
  characteristics 
      
    Time of day       
        0700 to <1700 3320 (52.3) 24996 (57.6) 11 3241 (52.4) 3314 (53.6) 2 
        1700 to <2400 2226 (35.1) 12086 (27.8) 16 2166 (35.0) 2060 (33.3) 4 
        0000 to <0700 800 (12.6) 6340 (14.6) 4 781 (12.6) 814 (13.2) 2 
    Seasonx       
        Fall 1502 (23.7) 11053 (25.5) 4 1475 (23.8) 1469 (23.7) 0 
        Winter 1446 (22.8) 9991 (23.0) 1 1412 (22.8) 1421 (23.0) 0 
        Spring 1635 (25.8) 11008 (25.4) 1 1585 (25.6) 1545 (25.0) 1 
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        Summer 1763 (27.8) 11370 (26.2) 4 1716 (27.7) 1753 (28.3) 1 
ED physician training       
    Emergency Medicine 4642 (73.1) 33336 (76.8) 8 4542 (73.4) 4541 (73.4) 0 
    Family Medicine 1338 (21.1) 7563 (17.4) 9 1289 (20.8) 1304 (21.1) 1 
    Other NR 2523 (5.7) 0 357 (5.8) 343 (5.5) 1 
       
ED patient acuity and wait 
times       
CTASy       
    1 and 2 1321 (20.8) 9072 (20.9) 0 1294 (20.9) 1290 (20.8) 0 
    3 3797 (59.8) 25241 (58.1) 3 3693 (59.7) 3736 (60.4) 1 
    4 and 5 1228 (19.4) 9108 (21.0) 4 1201 (19.4) 1162 (18.8) 2 
Time (hours) waiting for  
  physician assessment, mean  
  (SD) 
      
    CTAS 1 and 2 0.6 (0.8) 0.6 (0.9) 6 0.6 (0.8) 0.6 (0.8) 1 
    CTAS 3 1.3 (1.3) 1.4 (1.3) 5 1.3 (1.3) 1.3 (1.2) 2 
    CTAS 4 and 5 1.6 (1.4) 1.8 (1.6) 14 1.6 (1.4) 1.6 (1.4) 4 
90% percentile ED length of  
  stay, in hours       
    CTAS 1 and 2 9 8  9 8  
    CTAS 3 8 8  9 8  
    CTAS 4 and 5 8 8  8 8  
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CKD, chronic kidney disease; CT, computed tomography; CTAS, Canadian Triage Acuity Scale; ED, 
emergency department; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NR, not reported; SCr, serum creatinine; SD, standard deviation; SNRI, serotonin-
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. 
To convert SCr from SI units (µmol/L) to traditional units (mg/dL), divide by 88.42. 
a Data reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in 
the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients. 
b Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of 
individuals who live in the same region as the pharmacy that provided them with prescription medications.  
c Look-back window for co-morbidities was five years unless otherwise noted. 
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d Does not include angina. 
e Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus. 
f Look-back window for the Charlson co-morbidity index was two years.63,64 
g The Aggregated Diagnosis Groups (ADG) point score, derived from the John Hopkins Adjusted Clinical Groups® system, score is a weighted measure of health care utilization 
as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care 
involvement.65,66 The higher ADG score, the greater the co-morbidity. Individuals with an ADG score of 0 to 2 reflect low health care costs with no prior hospitalizations; ADG 
score 3 to 5, high health care costs but no prior hospitalizations; ADG score 6 or more, high health care costs and at least one prior hospitalization. 
h Look-back window for medication utilization was 120 days. 
i Patients in long-term care were identified from the Ontario Drug Benefit (ODB) database. 
j Percentages reported are based on the number of ODB program eligible patients (age 65 years and older). 
k Does not includes acetylsalicylic acid. 
l Pre-ED look-back window was 7 to 365 days. 
m CKD risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes consensus guidelines. In addition to using urine ACR measurements, urine dipstick 
and protein values were converted to an estimate urine ACR.67  
n Standardized difference was 9.6%. 
o Look-back window for health care utilization was 365 days unless otherwise noted. 
p Standardized difference was 10.1%. 
q Not specific for the assessment of the kidneys. 
r Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal. 
s For privacy considerations, individual hospital institutions were not identified. 
t Standardized to the mean number of ED registrations that occurred in the last 12-hour period over the last 14 days. 
u Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days. 
v Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days. 
w Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution’s number of ED registrations occurring in the last 24 hours. 
x Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20. 
y Patients with a CTAS of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a CTAS of 3 or 4 need to be seen 
within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a CTAS of 5 need to be seen within 120 minutes 80% of the time. 
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Table 5-7: Thirty-Day Risk of All-Cause Mortality and Need for Hospital-Based Acute 
Dialysis in a Matched Cohort of Patients in the Discharged Subpopulation 
 ED patient events, n (%)   
Outcome 
Discharged 
home with 
AKI 
(N = 6188) 
Discharged 
home with 
no AKI 
(N = 6188) 
Relative riska 
(95% CI) P value 
All-cause mortality 136 (2.2) 87 (1.4) 1.56 (1.20-2.04) 0.001 
 
Receipt of hospital- 
  based acute dialysis 
19 (0.3) 7 (0.1) 2.71 (1.22-6.02) 0.014 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; ED, emergency department. 
a Patients discharged home from the ED with no AKI served as the referent group. 
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Table 5-8: The Association Between Acute Kidney Injury and 30-Day All-Cause 
Mortality in the Discharged Subpopulation Examined in a Subgroup Defined by Pre-
Emergency Department Chronic Kidney Disease Stage 
 ED patient events, n/N (%)b   
Pre-ED CKD stagea 
Discharged 
home with 
AKI 
Discharged 
home with 
no AKI 
Relative riskc 
(95% CI) 
Interaction 
P value 
eGFR≥60 67/3904 (1.7) 47/3904 (1.2) 1.43 (0.99-2.06) 
0.57 45≤eGFR<60 34/1054 (3.2) 16/1054 (1.5) 2.13 (1.19-3.80) 30≤eGFR<45 16/803 (2.0) 13/803 (1.6) 1.23 (0.59-2.56) 
eGFR<30d 19/427 (4.4) 11/427 (2.6) 1.73 (0.83-3.59) 
Abbreviations: AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; ED, emergency 
department; eGFR, estimated glomerular filtration rate. 
a CKD stage was defined using eGFR categories, reported in mL/min/1.73m2. 
b n = number of events, N = number at risk. 
c Patients discharged home from the ED with no AKI served as the referent group. 
d Patients with an eGFR 15 to <30 were combined with patients with an eGFR <15 (but not on dialysis) to comply 
with ICES privacy regulations for reporting small numbers. 
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Chapter 6  
6 Discussion 
 
6.1 Summary of Findings 
In this population-based cohort study of adults discharged home from the ED with AKI, 
149 (2.3%) died within 30 days and this proportion increased with AKI severity. 
Compared to patients who were hospitalized with AKI, patients discharged home from 
the ED with AKI had a lower risk of death (3.0% vs. 11.9%) and a trend towards a lower 
risk of subsequent dialysis (0.4% vs 0.8%). Although the two groups in the AKI 
subpopulation had comparable characteristics, the divergence in outcomes highlights the 
accuracy of ED clinicians in discerning subtle clinical differences in patients with AKI. 
Sicker patients destined for worse outcomes were appropriately hospitalized. 
Nonetheless, the adverse outcomes of AKI following an ED discharge are clearly 
highlighted when the relative association between an ED discharge and mortality was 
attenuated with more severe forms of AKI. Furthermore, patients discharged home with 
AKI as compared to a similar cohort of ED patients discharged home with no AKI was 
associated with a 1.6-fold increase in mortality (2.2% vs. 1.4%) and an increased need for 
hospital-based acute dialysis (0.3% vs. 0.1%) within 30 days. Among the three groups 
studied, an ED discharge home with AKI represents an intermediate risk population. 
 
6.2 Interpretation of Findings 
6.2.1 Mortality 
The 30-day mortality risk in patients discharged home from the ED with AKI is not 
insignificant when compared to studies of other ED patient populations. For example, 
fewer patients died within 30 and 90 days of an ED discharge with chest pain (0.2%) and 
a transient ischemic attack (2%), respectively.90,91 Without conducting a formal analysis 
and accounting for differences in study methodology, the higher risk of mortality in our 
cohort is likely because of a greater burden of co-morbidity. Conversely, other studies 
showed that more patients died within 30 days of ED discharge with heart failure (4%) or 
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unstable angina (5%).92,93 The lower risk of mortality is likely because a proportion of 
AKI in our cohort may be caused by mild, reversible hemodynamic changes and 
therefore may confer better short-term outcomes. 
 
Two of the five studies we identified in our literature review examined mortality on 
patients discharged home from the ED with AKI. No deaths were observed within 30 
days of an ED discharge home with AKI among 31 patients.52 It is unclear whether the 
risk of 30-day mortality would be similar to our study had the authors examined a larger 
sample size. In the study by Holmes et al., the 90-day mortality for 2719 ED patients 
with AKI not hospitalized was 10-15%.50 A similar risk of 90-day mortality was observed 
by Talabani et al., although their study included patients diagnosed or managed either in 
the community or hospital setting.49 Future studies in our region could examine outcomes 
with a similar follow-up period. 
 
We found that most patients had mild AKI and that mortality was far more common than 
the need for hospital-based acute dialysis. In this setting, our study suggests that AKI 
may be a marker of illness severity.94 
 
6.2.1.1 Subgroup Analysis of the AKI Subpopulation 
We explored AKI stage as a subgroup in the analysis of the AKI subpopulation as prior 
studies demonstrated that severe forms of AKI confer worse outcomes.4,8,18–20 Our results 
demonstrated comparable mortality in a matched subgroup of patients with stage 3 AKI, 
where regardless of ED disposition, one in six patients with similar baseline 
characteristics died within 30 days of the index date. The high risk of mortality may 
reflect the progression of an underlying illness as approximately one-third of patients 
inevitably required admission to hospital within the same follow-up period. 
 
6.2.1.2 Subgroup Analysis of the Discharged Subpopulation 
We explored CKD stage as a subgroup in the analysis of the discharged subpopulation. 
CKD did not modify the association between AKI and short-term mortality. Prior studies 
suggest there is an interaction between AKI and CKD on mortality. In one study by Han 
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et al. showed that the presence of CKD exaggerated the association between AKI and the 
one-year risk of mortality in patients who had coronary artery bypass graft surgery.55 In 
our subgroup analysis, the effect of CKD on the association between AKI and mortality 
was not apparent within 30 days of an ED visit and could have been observed with longer 
follow-up periods. Another explanation is that we studied a group of patients whose 
characteristics and outcomes were unknown and who differ from patients with AKI in 
other clinical settings.42,43 How CKD modifies the association between AKI and mortality 
in non-hospitalized patients requires further study. 
 
6.2.2 Hospitalization and Follow-Up 
The need for hospitalization within 30 days of an ED discharge with AKI occurred in 
1032 (16.3%) patients. Our findings are similar to the 30-day readmission rates (15-20%) 
among AKI survivors discharged after hospitalization.95–97 We also found a discrepancy 
between a proportion of patients who received outpatient physician follow-up (68%) and 
those who had repeat SCr measurements (23%), raising questions on whether AKI was 
the main reason for the outpatient visit, physicians recognized the presence of AKI, or 
appropriate measures were taken to avoid hospitalization. Our findings suggest outpatient 
follow-up is inadequate, consistent with the study by Scheuermeyer et al. where only 4 of 
31 patients discharged home from the ED with AKI received renal-specific follow-up.52 
 
6.3 Study Strengths  
This is the first comprehensive study to examine the characteristics and outcomes of 
patients discharged home from the ED with AKI. We are not aware of any studies 
describing this group since the publication of this work.47 None of the studies identified 
in our literature review examined the AKI subpopulation as the primary cohort of 
interest.48–52 
 
Using a combination of administrative and laboratory databases at ICES, we were able to 
obtain a large sample size and examine clinically important outcomes. With a large 
number of baseline characteristics available, we were able to provide context for these 
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outcomes using propensity scores and two ED referent groups. Finally, we were able to 
use most current definition for the diagnosis and staging of AKI with SCr 
concentrations.14 We ascertained patients who would have otherwise been missed had we 
exclusively relied on diagnostic codes.41 As shown on Figure 5-1, only 56 patients 
discharged home from the ED were assigned an ICD-10 code for AKI. 
 
6.4 Limitations 
6.4.1 Generalizability 
Our results are generalizable to residents in Southwestern Ontario captured by our data 
sources. We had access to SCr concentrations from two laboratory databases. The Cerner 
electronic health record is used in 13 hospital institutions and Dynacare Medical 
Laboratories represents approximately one-third of Ontario residents.60,61 We could not 
obtain patients who had pre-ED visit baseline SCr measurements done in other outpatient 
laboratories or hospitals in Ontario. 
 
In the analysis of the AKI and discharged subpopulations, our results are generalizable to 
patients included in the match. We could not match 1967 (31%) patients in the AKI 
subpopulation and 158 (3%) patients in the discharged subpopulation using our 
propensity score models. Furthermore, medication information was only available for a 
subset of patients eligible for universal drug coverage. We minimized the impact of 
missing medication information by balancing the co-morbidities for which these 
medications are indicated. 
 
6.4.2 Interpretation of Findings 
Factors such as hemodynamic stability and the ED physician’s clinical assessment of 
patient safety and appropriateness for discharge home cannot be ascertained by 
administrative data. We also could not determine with certainty if ED physicians did not 
recognize the AKI. For many patients, we suspect that AKI was in fact recognized, 
appropriately managed, and deemed safe for discharge home.52 Further details would 
require a detailed chart review best collected in a prospective fashion. 
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A significant proportion of individuals discharged home from the ED with AKI required 
hospitalization within 30 days. We are unable to establish if the need for hospitalization 
was preventable or inevitable. Patients may have been appropriately hospitalized after 
being strategically discharged from a rural ED and instructed to seek further care at a 
tertiary care centre. Such patients would be considered an ED discharge. 
 
6.4.3 Selection Bias 
We excluded patients discharged home from the ED with an improvement in AKI 
severity (1695 patients) and those assigned an ICD-10 code for AKI (56 patients). These 
individuals may differ systematically from those who did not have an improvement in 
AKI severity or were recognized by physicians with an ED main diagnosis of AKI.98 We 
elected to restrict our analysis to a specific group of patients less likely to be recognized 
and treated by ED physicians because we felt these patients would most likely benefit 
from an intervention that combines active surveillance and increased awareness with 
timely renal-specific outpatient follow-up (Chapter 6.5). Interpretation of the 
characteristics and outcomes of our main cohort and two matched analyses should bear 
this limitation in mind. 
 
6.4.4 Residual Confounding 
Our results are subject to confounding as propensity score matching will only ensure 
balance on measured characteristics. We did not include the ED main diagnosis in our 
propensity score models as the diagnosis is often preliminary and there is significant 
disagreement with main diagnoses assigned at later stages of patient care.99–101 There was 
also significant variability in the ED main diagnosis assigned to patients (Appendix H). 
Inclusion of the ED main diagnosis would have resulted in very few matched patients. 
Although the exclusion of the ED main diagnosis is a source residual confounding, we 
felt it was both valuable and worthwhile to provide health care providers context for our 
outcomes. 
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6.5 Study Implications 
6.5.1 Recommendations for Future Research 
We restricted our cohort to a very specific group of patients with AKI. Additional studies 
could be performed to include patients with AKI who were excluded from our main 
cohort. Future data sets linked at ICES may include larger laboratory databases more 
representative of all residents in Ontario. We would also be able to include new baseline 
characteristics and help confirm the association between an ED discharge home with AKI 
and mortality. However, there are several other knowledge gaps in this area that warrant 
further attention. A prospective chart review would be required to understand why some 
patients are at high risk of death or early hospitalization and to establish the reasons for a 
discrepancy between the proportion of outpatient physician visits and kidney function 
testing. Additional research is required to ascertain differences in patient characteristics 
between those destined for adverse outcomes and poor outpatient follow-up. Finally, 
future studies could examine long-term outcomes similar to those done for survivors of 
AKI patients after hospitalization.22,26,28 
 
6.5.2 Health System Strategies 
There is an opportunity to explore health system strategies to improve the identification 
and management of patients discharged home from the ED with AKI. Studies have 
demonstrated that rapid access clinics for patients discharged home from the ED with 
chest pain, heart failure, or a transient ischemic attack can improve patient outcomes.102–
104 Furthermore, AKI survivors discharged after hospitalization appear to benefit from 
follow-up clinics.30 A similar model could be adapted for patients discharged home from 
the ED with AKI, supported by an automated surveillance system to facilitate AKI 
identification and increased awareness by all health care providers.105 AKI surveillance 
systems have become increasingly popular in the United Kingdom and could serve as a 
model for design and implementation to improve the process of care for patients in our 
region.50 
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6.6 Conclusion 
Patients with moderate-to-severe AKI at significant risk of 30-day adverse outcomes such 
as all-cause mortality and subsequent hospitalization. Compared to a hospital admission 
with AKI and an ED discharge with no AKI, patients discharged home from the ED with 
AKI are an intermediate risk population. Additional research into risk factors for adverse 
outcomes, further characterization of ED and outpatient care, and testing health system 
strategies to identify and mitigate gaps in care appears warranted. 
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Appendices 
Appendix A: MEDLINE/Ovid Search Strategy to Identify Studies Describing Patients 
Discharged Home from the Emergency Department with Acute Kidney Injury. 
# MEDLINE/Ovid search Resultsa 
1b ((acute adj2 (kidney or renal or nephr$ or glomer$ or h?emodialy$ or 
dialysis)).mp OR exp Acute Kidney Injury/ OR ((kidney or renal) adj 
injur$).tw OR exp Kidney Diseases/ci OR (tubul$ adj (injury or 
necrosis or damage)).tw OR nephrotox$.tw OR Nephritis, Interstitial/ 
OR ((tubulointerstitial or interstitial) adj nephr$).tw OR ((kidney$ or 
renal) adj isch?emi$).tw OR (induced adj (kidney or renal)).tw OR (h? 
emolytic ur?emi$).tw OR *Hemolytic-Uremic Syndrome/ OR aki.tw 
OR oliguri$. mp or anuri$.mp OR anti-glomerular.mp OR 
antiglomerular.mp OR Kidney Cortex Necrosis/ OR pre-renal.tw or 
prerenal.tw OR anti-gbm.tw OR (obstruct$ adj2 (kidney$ or 
nephropath$ or renal or uropathy)).tw OR hepatorenal syndrome. mp 
OR *Hemorrhagic Fever with Renal Syndrome/ OR (thrombotic adj 
(thrombocytopeni$ or microangiopathy)).tw OR exp Acidosis/ci OR 
renal hypoperfusion.tw OR (worsening and renal).tw OR ((improved 
or recover$ or impair$) adj2 renal function).tw OR azot?emi$.mp OR 
(renal adj2 thrombosis).tw OR ((Reperfusion Injury/ OR 
(isch?emi$ adj (reperfusion or injury)).tw OR (critical$ adj (care or 
ill$ or patient$)).mp OR sepsis.mp OR septic.mp OR intensive care.mp 
OR icu.tw OR tubular cell$.tw OR rhabdomyolysis.mp OR 
thrombocytopeni$.tw OR life-threatening.mp OR vasculit$.mp OR 
polyarteritis.mp OR ((multi$ organ or multiorgan) adj (failure or 
dysfunction)).mp OR cardiogenic shock.tw OR Blood Urea Nitrogen/ 
OR polyangiitis.mp OR wegener$ granulomatosis.mp) AND 
(kidney.mp OR renal.mp OR dialysis.mp OR ur?emi$.tw OR 
dehydrat$.mp OR creatinin$.mp)) OR (nephropath$ AND 
((contrast$ adj (medi$ OR induced OR agent$)) OR radiocontrast$ OR 
iodinated OR crystal$ OR cast)).mp. OR ((glomerulonephritis.mp OR 
nephrit$.tw) AND (acute.tw OR crescentic.mp OR anca$.tw OR 
rapidly progressive.tw)) OR ((Kidney Diseases/ OR (renal adj 
(insufficienc$ or failure or function or impairment)).mp OR ischemia- 
reperfusion injury.tw OR glomerular filtration rate.tw) AND (exp 
*Cardiovascular Surgical Procedures/ OR Cardiovascular Diseases/ 
OR exp *Cardiovascular System/ su OR cardiac surg$.mp OR 
cardiopulmonary.tw OR Ischemia/ OR exp *diagnostic imaging/ OR 
exp Neurologic Manifestations/ OR *Contrast Media/ OR 
preoperative$.tw OR pre-operative$.tw OR postoperative$.tw OR 
post-operative$. tw OR exp Substance-Related Disorders/ OR 
microangiopath$.tw OR cirrhosis.ti OR revers$.tw OR ci.fs)) OR 
((injury.mp or isch?emi$.mp or reperfusion.mp or contrast medi$.mp) 
AND (renal tubul$.tw or tubular.tw))) 
257042 
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2c Emergency Treatment/ or Emergency Medicine/ or emergency medical 
services/ or emergency service, hospital/ or trauma centers/ or triage/ 
or exp Evidence-Based Emergency Medicine/ or exp Emergency 
Nursing/ or Emergencies/ or emergicent* or casualty department* or 
((emergenc* or ED) adj1 (room* or accident or ward or wards or unit 
or units or department* or physician* or doctor* or nurs* or 
treatment*orvisit*)).mp. or (triage or critical care or (trauma adj1 
(cent* or care))).mp 
275615 
3 (communit$ OR community OR community-acquired OR community 
acquired OR outpatien$ OR ambul$ OR ambul$ care OR primar$ care) 
890577 
4 1 and 2 7694 
5 1 and 3 5924 
6 4 or 5 13251 
7 Limit 6 to English language 11465 
a Results are up to date as of August 10, 2017 and excludes the citation related to this thesis.47 
b Search filters for acute kidney injury are described by Hildebrand et al.45 
c Search filters for emergency department studies are described by Campbell, S.44
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Appendix B: Checklist of Recommendations for Reporting of Observational Studies Using the STrengthening the Reporting of 
OBservational Studies in Epidemiology (STROBE) Guidelines 
Section Item no. Recommendation Reported 
Title and        
  abstract 
1a Indicate the study’s design with a commonly used term in the title or the abstract i 
1b Provide in the abstract an informative and balanced summary of what was done 
and what was found 
ii 
Introduction 
Background 2 Explain the scientific background and rationale for the investigation being 
reported 
Chapters 1-2 
Objectives 3 State specific objectives, including any prespecified hypotheses Chapter 3 
 
Methods 
Study design 4 Present key elements of study design early in the paper Chapter 4 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Chapter 4 
Participants 6 Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up. 
Chapter 4 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
Chapter 4 
Data sources and  
  measurement 
8 For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
Chapter 4 
Bias 9 Describe any efforts to address potential sources of bias Chapter 4 
Study size 10 Explain how the study size was arrived at Chapter 4 
Quantitative 
Variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
Chapter 4 
Statistical methods 12a Describe all statistical methods, including those used to control for confounding Chapter 4 
12b Describe any methods used to examine subgroups and interactions Chapter 4 
12c Explain how missing data were addressed Chapter 4 
12d If applicable, explain how loss to follow-up was addressed Not applicable 
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12e Describe any sensitivity analyses Not applicable 
Results 
Participants 13a Report numbers of individuals at each stage of study—e.g. numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed  
Chapter 5 
13b Give reasons for non-participation at each stage Chapter 5 
13c Consider use of a flow diagram Chapter 5 
Descriptive data 14a Give characteristics of study participants (e.g. demographic, clinical, social) and 
information on exposures and potential confounders  
Chapter 5 
14b Indicate number of participants with missing data for each variable of interest Chapter 5 
14c Summarise follow-up time (e.g., average and total amount) Chapter 5 
Outcome data 15 Report numbers of outcome events or summary measures over time Chapter 5 
Main results 16 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (e.g., 95% confidence interval). Make clear which confounders 
were adjusted for and why they were included 
Chapter 5 
Report category boundaries when continuous variables were categorized Chapter 5 
If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Chapter 5 
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and 
sensitivity analyses 
Chapter 5 
Discussion 
Key results 18 Summarise key results with reference to study objectives Chapter 6 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias. 
Chapter 6 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Chapter 6 
Generalizability 21 Discuss the generalizability (external validity) of the study results Chapter 6 
 
Other information 
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Funding 22 Give the source of funding and the role of the funders for the present study and, 
if applicable, for the original study on which the present article is based 
Acknowlege-
ments 
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Appendix C: Coding Definitions for Co-Morbid Conditions 
Variable Database Code set Code 
Abdominal aortic  
  aneurysm repair 
CIHI-DAD CCP 5024, 5034 
CCI 1KA76 
OHIP Fee code R802, R816, R817, R783, R784, R785, R814 
Atrial fibrillation or  
  flutter 
CIHI-DAD ICD-9 4273 
 ICD-10 I48 
Major cancera CIHI-DAD ICD-9 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 205, 206, 207, 208, 2303, 
2304, 2307, 2330, 2312, 2334 
ICD-10 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 991, 993, C15, C18, C19, 
C20, C22, C25, C34, C50, C56, C61, C82, C83, C85, C91, C92, C93, C94, 
C95, D00, D010, D011, D012, D022, D075, D05 
OHIP Diagnosis 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174, 175, 183, 185 
Chronic liver disease CIHI-DAD ICD-9 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824, V026, 571, 2750, 2751, 
7891, 7895  
ICD-10 B16, B17, B18, B19, I85, R17, R18, R160, R162, B942, Z225, E831, E830, 
K70, K713, K714, K715, K717, K721, K729, K73, K74, K753, K754, K758, 
K759, K76, K77 
OHIP Diagnosis 571, 573, 070 
Fee code Z551, Z554 
Chronic obstructive  
  pulmonary disease 
CIHI-DAD ICD-9 491, 492, 496 
ICD-10 J41, J43, J44 
Coronary artery  
  disease (excluding  
  angina) 
CIHI-DAD CCP 4801, 4802, 4803, 4804, 4805, 481, 482, 483 
CCI 1IJ50, 1IJ76 
ICD-9 412, 410, 411 
ICD-10 I21, I22, Z955, T822 
OHIP Diagnosis 410, 412 
Fee code R741, R742, R743, G298, E646, E651, E652, E654, E655, Z434, Z448  
Dementia CIHI-DAD ICD-9 2900, 2901, 2903, 2904, 2908, 2909, 2948, 2949, 3310, 3311, 3312, 2941, 797 
ICD-10 F065, F066, F068, F069, F09, F00, F01, F02, F03, F051, G30, G31, R54 
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OHIP Diagnosis  290, 331, 797 
Diabetesb CIHI-DAD ICD-9  250 
ICD-10 E10, E11, E13, E14 
OHIP Diagnosis 250 
Fee code Q040, K029, K030, K045, K046 
Heart failure CIHI-DAD ICD-9 425, 5184, 428, 514 
ICD-10 I500, I501, I509, I255, J81 
CCP 4961, 4962, 4963, 4964 
CCI 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR 
OHIP Diagnosis 428 
Fee code R701, R702, Z429 
Hypertensionb CIHI-DAD ICD-9 401, 402, 403, 404, 405 
ICD-10 I10, I11, I12, I13, I15  
OHIP Diagnosis 401, 402, 403 
Nephrolithiasis CIHI-DAD ICD-9 5920, 5921, 5929, 5940, 5941, 5942, 5948, 5949, 27411 
ICD-10 N200, N201, N202, N209, N210, N211, N218, N219, N220, N228 
Osteoarthritis CIHI-DAD ICD-9 715 
ICD-10 M15, M16, M17, M18, M19, M47 
Parkinson’s disease CIHI-DAD ICD-9 332 
ICD-10 G20, F023 
Peripheral vascular 
disease 
CIHI-DAD ICD-9 4402, 4408, 4409, 5571, 4439, 444 
ICD-10 I700, I702, I708, I709, I731, I738, I739, K551  
CCP 5125, 5129, 5014, 5016, 5018, 5028, 5038, 5126, 5159  
CCI 1KA76, 1KA50, 1KE76, 1KG50, 1KG57, 1KG76MI, 1KG87, 1IA87LA, 
1IB87LA, 1IC87LA, 1ID87LA, 1KA87LA, 1KE57 
OHIP Fee code R787, R780, R797, R804, R809, R875, R815, R936, R783, R784, R785, E626, 
R814, R786, R937, R860, R861, R855, R856, R933, R934, R791, E672, R794, 
R813, R867, E649 
Rheumatoid arthritis CIHI-DAD ICD-9 714 
ICD-10 M05, M06 
OHIP Diagnosis 714 
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Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian 
Institute for Health Information Discharge Abstract Database; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, 
Tenth Revision; OHIP, Ontario Health Insurance Plan. 
a List of major cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, and esophageal cancers. 
b Oral hypoglycemic medications and insulin were not considered as not all patients have medication information available. 
c Cerebrovascular disease: stroke or transient ischemic attack. 
  
Cerebrovascular 
diseasec 
CIHI-DAD ICD-9 430, 431, 432, 4340, 4341, 4349, 435, 436, 3623 
ICD-10 I62, I630, I631, I632, I633, I634, I635, I638, I639, I64, H341, I600, I601, I602, 
I603, I604, I605, I606, I607, I609, I61, G450, G451, G452, G453, G458, G459, 
H340 
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Appendix D: Diagnostic Codes for Health Care Utilization Characteristics 
Variable Database Code set Code 
Family physician  
  visit 
OHIP Fee code A001, A003, A004, A005, A006, A007, A008, A900, A901, A905, A911, 
A912, A967, K131, K132, K140, K141, K142, K143, K144, W003, W008, 
W121 
IPDB Main 
specialty 
GP/FP 
Internal medicine  
  physician visit 
OHIP Fee code A135, C135 
IPDB Main 
specialty 
INTERNAL MEDICINE 
Nephrologist visit OHIP Fee code A135, A161, A163, A164, A165, A166, A168, C101, C138, G860, G323, 
G333, E083, C132, C135, C137, C139, H540, G325, G326, G860, G865, 
G866, G330, G331, G332, G861, G864 
 IPDB Main 
specialty 
NEPHROLOGY 
Urologist visit OHIP Fee code A355, A356, A353, A354, C355, C356, C353, C354 Z606, Z628, Z632, Z633, 
Z634, S655, S654 
 IPDB Main 
specialty 
UROLOGY 
Coronary  
  angiogram or  
  revascularization 
CIHI-DAD CCP 4892, 4893, 4894, 4895, 4896, 4897, 4898, 481, 482, 483, 480 
CCI  3IP10, 3IS10, 1IJ50, 1IJ26, 1IJ27, 1IJ57, 1IJ76, 1IJ57GQ, 1IJ54GQAZ 
OHIP Fee code  G297, G509, R741, R742, R743, E651, E652, E654, E646, G298, Z434, G262 
CT scan with  
  contrast 
CIHI-DAD CCI 3AF20WC, 3AN20WC, 3CA20WC, 3DR20WC, 3EA20WC, 3EL20WC, 
3ER20WC, 3EY20WC, 3FX20WC, 3FY20WC, 3GE20WC, 3GT20WC, 
3GY20WC, 3ID20WC, 3IP20WC, 3JE20WC, 3JX20WC, 3JY20WC, 
3KE20WC, 3KG20WC, 3KT20WC, 3NM20WC, 3OT20WC, 3PC20WC, 
3PZ20WC, 3QT20WC, 3SC20WC, 3SF20WC, 3TZ20WC, 3VZ20WC, 
3WZ20WC, 3YM20WC, 3ZZ20WC, 3FY20VZ, 3FY20VC 
Echocardiogram CIHI-DAD CCP 0282  
CCI 3IP30 
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CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI-DAD, Canadian Institute for Health 
Information Discharge Abstract Database; CT, computed tomography; OHIP, Ontario Health Insurance Plan. 
a G560, G561, G562, G566, G567, G568, G576 are no longer in fee schedule as of 2014/11. 
b An abdominal ultrasound is not specific to the kidneys. 
c Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal. 
 
 
  
OHIP Fee codea G560, G561, G562, G566, G567, G568, G570, G571, G572, G574, G575, 
G576, G577, G578, G581 
Cardiac stress test CIHI-DAD CCP 0341, 0342, 0343, 0344, 0605  
CCI 2HZ08, 3IP70 
OHIP Fee code G315, G174, G111, G112, G319, G582, G583, G584, J607, J608, J807, J808, 
J809, J866, J609, J666 
Abdominal  
  ultrasoundb 
OHIP Fee code J128, J135, J428, J435 
Kidney stone  
  interventionsc 
OHIP Fee code Z630, Z628, E760, E761, Z624, Z627 
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Appendix E: Diagnostic Codes for Exclusion Criteria 
Variable Database Code set Code 
Dialysis CIHI-DAD ICD-9 V451, V560, V568, 99673 
ICD-10 T824, Y602, Y612, Y622, Y841, Z49, Z992 
CCP 5127, 5142, 5143, 5195, 6698 
CCI 1PZ21, 1OT53DATS, 1OT53HATS, 1OT53LATS, 1SY55LAFT, 7SC59QD, 
1KY76, 1KG76MZXXA, 1KG76MZXXN, 1JM76NC, 1JM76NCXXN 
OHIP Fee code R850, G324, G336, G327, G862, G865, G099, R825, R826, R827, R833, 
R840, R841, R843, R848, R851, R946, R943, R944, R945, R941, R942, 
Z450, Z451, Z452, G864, R852, R853, R854, R885, G333, H540, H740, 
R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861, 
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294, 
G295 
Kidney  
  transplant 
CIHI-DAD CCI 1PC85 
OHIP Fee code S435, S434 
Palliative care CIHI-DAD PATSERV 58 
OHIP Fee code C945, C882, C982, W872, W972, B966, B998, B997, G511, W882, W982, 
K023 (inpatient or LTC use only) 
AKI CIHI-DAD/ 
NACRS 
ICD-10 N17 
Abbreviations: AKI; acute kidney injury; CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; 
CIHI-DAD, Canadian Institute for Health Information Discharge Abstract Database; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International 
Classification of Diseases, Tenth Revision; NACRS, National Ambulatory Care Reporting System; OHIP, Ontario Health Insurance Plan; PATSERV, patient service. 
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Appendix F: Diagnostic Codes for Outcome Variables 
Abbreviations: ACR, albumin-to-creatinine ratio; ADP, Assistive Devices Program; CAPE, Client Agency Program Enrolment; CCRS, Continuing Care Reporting System; CIHI-
DAD, Canadian Institute for Health Information Discharge Abstract Database; GP/FP, general practitioner/family physician; HCD, Home Care Database; ICES, Institute for 
Clinical Evaluative Sciences; IPDB, ICES Physician Database; NACRS, National Ambulatory Care Reporting System; NRS, National Rehabilitation Reporting System; ODB, 
Variable Database Code set Code 
Mortality RPDB Vital status Vital status field 
Receipt of hospital-based acute  
  dialysis 
OHIP Fee code R849, G323, G866, G330, G331, G093, G095, G294, 
G2955 associated with hospital admission 
Health care cost ADP, CAPE, CCRS, 
CIHI-DAD/NACRS, 
HCD, NRS, ODB, 
OHIP, OMHRS 
 ICES costing macro62 
Outpatient physician visit by  
  any one of: 
    Family physician 
    General internist 
    Nephrologist 
    Urologist 
OHIP Fee code GP/FP: A001, A003, A004, A005, A006, A007, A008, 
A900, A901, A905, A911, A912, A967, K131, K132, 
K140, K141, K142, K143, K144, W003, W008, W121 
Internal Medicine: A135, C135 
Nephrology: A135, A161, A163, A164, A165, A166, 
A168, C101, C138, G860, G323, G333, E083, C132, 
C135, C137, C139, H540, G325, G326, G860, G865, 
G866, G330, G331, G332, G861, G864 
Urology: A355, A356, A353, A354, C355, C356, C353, 
C354 Z606, Z628, Z632, Z633, Z634, S655, S654 
IPDB Main 
specialty 
GP/FP, INTERNAL MEDICINE, NEPHROLOGY, 
UROLOGY 
SCr measurement Dynacare  067A 
Cerner  Test done=”A” 
OHIP Fee code L067 
Urine protein measurement  
  (dipstick, ACR, or PCR) 
Dynacare  05DR, 05DU, P/CR, P/CM, 208Y, 208Z, 253 
 
OHIP Fee code L253, L254, L255, L633, L634, L641, G009, G010 
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Ontario Drug Benefit; OHIP, Ontario Health Insurance Plan; OMHRS, Ontario Mental Health Reporting System; PCR, protein-to-creatinine ratio; RPDB, Ontario’s Registered 
Persons Database; SCr, serum creatinine. 
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Appendix G: Characteristics Used to Derive Propensity Scores for the AKI Subpopulation and Discharged Subpopulation 
Category Variable Number of variablesa 
Demographics Age, sex, income quintile, year of cohort entry, rural location, long-term care status, Pharmacy 
forward sortation area 
7 
Co-morbid  
  conditions 
Abdominal aortic aneurysm repair, atrial fibrillation/flutter, cerebrovascular disease, chronic 
liver disease, chronic obstructive pulmonary disease, coronary artery disease, dementia, 
diabetes, heart failure, hypertension, major cancer, nephrolithiasis, osteoarthritis, Parkinson’s 
disease, peripheral vascular disease, rheumatoid arthritis,  
16 
Co-morbidity  
  indices 
Charlson co-morbidity index, Aggregated Diagnosis Group point score 2 
Laboratory  
  characteristics 
Pre-ED visit baseline SCrb, number of days pre-ED visit baseline SCr was measuredb, pre-ED 
visit baseline SCr ≤50 µmol/L, SCr value at ED visitb, urine ACR, serum potassiumb, serum 
sodiumb, AKI stage, eGFR category 
9 
Health care  
  utilization 
Prior hospitalizations, prior ED visits, family physician visit, general internist visit, 
nephrologist visit, urologist visit, coronary angiogram or revascularization, CT scan with 
contrast, echocardiogram, cardiac stress test, abdominal ultrasound, intervention for kidney 
stones 
12 
Medication  
  characteristics  
  and classesd 
ODB program eligibility, number of unique drug identification numbers, number of unique 
drug names 
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, alpha-1-
adrenoceptor antagonist or 5-alpha-reductase inhibitor, antibacterial, anticoagulant, 
antidepressant (SSRI or SNRI), antineoplastic, antiplatelet, antipsychotic medication, beta-
adrenergic antagonist, calcium channel blocker, corticosteroid, xanthine oxidase inhibitor or 
uricosuric agent, anti-retroviral medication, immunosuppressive medication, lithium, non-
potassium sparing diuretic, non-steroidal anti-inflammatory drug, oral hypoglycemic agent or 
insulin, potassium-sparing diuretic, , proton pump inhibitor, statin 
24 
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ED and hospital  
  characteristics 
Institution (1-13)c, ED registrations in last 12 hoursb, hospital admissions in last 24 hoursb, 
hospital discharges in last 24 hoursb, proportion of ED registrations admitted to hospital, ED 
length of stayb, time waiting for physician assessmentb, Canadian Triage Acuity Scale, time of 
day, season of the year, ED physician specialty training. 
23 
 Total 93 
Abbreviations:  ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; CT, computed tomography; ED, emergency department; eGFR, estimated glomerular filtration rate; 
ODB, Ontario Drug Benefit; SCr, serum creatinine; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor. 
a We considered 93 variables to derive propensity scores for the AKI and discharged subpopulations. In the AKI subpopulation (comparing patients discharged home from the ED 
with AKI versus patients admitted to hospital with AKI), 92 variables were used to derive the propensity score. The ED length of stay variable was not included because 
admitted patients may remain in the ED until an inpatient bed is available, inflating the ED length of stay (defined as time of registration to time patient physically left the ED). 
In the discharged subpopulation (comparing patients discharged home from the ED with AKI versus patients discharged home from the ED with no AKI), 91 variables were 
used to derive the propensity score. ED visit SCr and AKI stage were not included in the model. 
b Continuous variables used to derive propensity scores for both the AKI and discharged subpopulation. 
c Each hospital institution (13 total) was included to derive propensity scores for both the AKI and discharged subpopulation. For privacy considerations, individual hospital 
institutions were not identified. 
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Appendix H: Most Common Main Diagnoses Assigned by Physicians to a Cohort of 
6346 Patients Discharged Home from the Emergency Department with Acute Kidney 
Injury 
No. ICD-10 Description n (%) 
1 R07 Pain in throat and chest 515 (8.1%) 
2 R10 Abdominal and pelvic pain 447 (7.0%) 
3 N23 Unspecified renal colic 309 (4.9%) 
4 N39 Other disorders of urinary system 248 (3.9%) 
5 R55 Syncope and collapse 219 (3.5%) 
6 J18 Pneumonia, organism unspecified 175 (2.8%) 
7 R53 Malaise and fatigue 159 (2.5%) 
8 K52 Other noninfective gastroenteritis and colitis 150 (2.4%) 
9 E86 Volume depletion 128 (2.0%) 
10 I48 Atrial fibrillation and flutter 123 (1.9%) 
11 R06 Abnormalities of breathing 116 (1.8%) 
12 R42 Dizziness and giddiness 116 (1.8%) 
13 N20 Calculus of kidney and ureter 111 (1.7%) 
14 I50 Heart failure 110 (1.7%) 
15 R11 Nausea and vomiting 98 (1.5%) 
16 I20 Angina pectoris 89 (1.4%) 
17 L03 Cellulitis 88 (1.4%) 
18 A09 Diarrhoea and gastroenteritis of presumed infectious 
origin 
77 (1.2%) 
19 J44 Other chronic obstructive pulmonary disease 77 (1.2%) 
20 R00 Abnormalities of heart beat 76 (1.2%) 
Abbreviation: ICD, International Classification of Diseases. 
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